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NOTCH SIGNALING 
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in Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
(in Biochemistry and Molecular Biology) 
May, 2007 
Notch signaling is associated with activation of either oncogenic or tumor 
suppressor activities. The human mammary adenocarcinoma cell line, MDA-MB-231, 
was characterized in vitro and in xenografts in vivo to test the hypothesis that activation 
of Notch signaling regulates mammary tumor phenotype. Notch 1, Notch2, and Notch4 
signaling was compared by stable expression of their constitutively active intracellular 
domains (ICD). Notch4 activation led to enhanced tumorigenicity, in addition to 
increased cell proliferation and survival in vitro, whereas the activation of Notch 1 or 
Notch2 decreased cell proliferation and survival, in which Notch2 increased apoptosis. 
Stably transfected cell lines were additionally studied in vivo as xenografts. 
Overexpression of Notch4ICD promoted tumor growth which resulted in a three-fold 
increase in tumor volume than control. Conversely, Notch IICD or Notch2ICD led to 
decreased tumor penetrance and significantly smaller, necrotic tumors. Analysis of cell 
proliferation showed a positive correlation to tumor size. Notch4ICD tumors showed an 
increase in organized vasculature. Control tumors and Notch 1ICD tumors, in contrast, 
showed significant necrosis, and had fewer vessels. Although Notch2ICD tumors were 
small and showed low proliferation, they were highly vascularized, comparable to 
Notch4ICD tumors. The molecular profile of the Notch4ICD tumors showed specific 
induction of VEGF and HGF in the tumors and host plasma, suggesting a differential 
regulation of angiogenic cytokines. The stark contrast between distinct Notch receptors 
suggests potential antagonistic interactions between Notchl/Notch2 and Notch4 in 
mammary tumorigenesis. Further, the combination of cell proliferation and 
vascularization contribute differentially to overall tumor phenotype. 
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1. BACKGROUND 
1.1 The Notch receptors 
The gene encoding the Notch receptor was discovered in flies by observation that 
partial loss of function results in notches at the wing margin (1). The Notch gene was 
cloned in the mid-1980s by the Artavanis-Tsakonas (2) and Young (3-5) laboratories, and 
it was subsequently discovered that the Notch gene encodes a transmembrane receptor 
whose signaling pathway is highly conserved throughout evolution (6). 
The family of Notch receptors mediates short-range cell interactions primarily 
involved in binary cell fate decisions during the development of all metazoa. These cell 
fate decisions can be of two kinds. The first is enabling a cell to adopt a new fate or 
remain in its original state; the second is associated with differentiative cell division, in 
which the daughter cells can adopt one of two fates. In both instances, Notch activation 
favors one fate over the other. This strategy of selection of alternative fates is central to 
the process generically known as "lateral inhibition," in which a population of cells share 
a developmental potential but only some of these cells achieve that fate. Cells that adopt 
the fate activate Notch in surrounding cells to suppress those cells from adopting the 
same fate. 
Classic embryonic analyses of lethal loss-of-function mutations, conducted by 
Poulson (7), demonstrated the classical Notch "neurogenic" phenotype, where cells 
destined to become epidermis switch fate and give rise to neural tissue. Subsequent 
studies in flies and vertebrates further characterized Notch function in neurogenesis, and 
from these studies, it became evident that Notch acts at different stages of development 
even within one tissue. 
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The Notch gene in Drosopila melanogaster encodes a 300kD single pass 
transmembrane receptor. The precise numbers of Notch paralogues differs between 
species. In Drosophila, there is one Notch gene (2) and there are two in Caenhorhabditis 
elegans, LIN-12 (8) and GLP-1 (9). In vertebrates, there are four Notch receptors: Notch 1 
(10), Notch2 (11), Notch3 (12) and Notch4 (13). Table 1 illustrates the protein sequence 
homology between each Notch in Drosphila, mouse, and human. The basic signaling 
paradigm is common throughout the species, and is very unlike the classical signaling 
pathways involving cascades of protein kinases (14-16). 
hNotchl 
hNotch2 
hNotch3 
hNotch4 
mNotchl 
mNotch2 
mNotch3 
mNotch4 
dNotch 
hNl 
45 
50 
45 
82 
56 
48 
45 
39 
hN2 
45 
44 
15 
45 
86 
45 
13 
35 
hN3 
50 
44 
43 
48 
48 
83 
25 
40 
hN4 
45 
15 
43 
44 
15 
15 
81 
22 
mNl 
82 
45 
48 
44 
56 
48 
43 
39 
mN2 
56 
86 
48 
15 
56 
49 
25 
47 
mN3 
48 
45 
83 
15 
48 
49 
18 
41 
mN4 
45 
13 
25 
81 
43 
25 
18 
12 
dNotch 
39 
35 
40 
22 
39 
47 
41 
12 
Table 1. Notch homology during evolution. 
Shown is percent homology of amino acid sequence over entire protein length. 
1.1.1 Structure of the Notch receptor 
The Notch receptor is a single pass non-covalently bound heterodimeric 
transmembrane molecule. It is synthesized in the trans-golgi network as a large precursor 
protein where it is cleaved into two subunits by a furin-like protease (SI cleavage) (17). 
This cleavage occurs between the LNR (Lin-12 Notch Repeats) and the transmembrane 
domain generating two polypeptides that remain associated through a noncovalent 
2 
interaction requiring divalent cations (18). A furin-like convertase enzyme is responsible 
for this cleavage in mammalian tissue culture cells (19). This processing is required for 
signaling in mammals (19), but is dispensable in flies (20). The resultant two subunits 
genereated from the SI cleavage consist of 1) the majority of the extracellular domain 
and 2) a small part of the extracellular domain and the complete transmembrane and 
intracellular domains. These two subunits associate noncovalently, resulting in the cell-
surface accumulation of mature heterodimeric type I transmembrane receptors. However, 
full-length uncleaved Notch can be found at the cell surface, and there is some evidence 
to suggest it is functional (21). 
The Drosophila Notch has a large extracellular domain containing 36 tandem 
,EGF (Epidemal Growth Factor)-like repeats and three LNRs (3, 6, 22, 23). However 
subsequent analysis of the Notch receptors in other species found that the number of 
EGF-like repeats varies between the receptors. The Drosophila Notch protein contains 
36 extracellular EGF-like repeats, followed by three LNR, a transmembrane domain, an 
RBPJK associated molecule (RAM) region, seven cdclO/ankyrin repeats (24), a nuclear 
localization sequence (NLS), and a C-terminal extension with PEST sequences. The 
worm proteins are highly related in structure, although somewhat smaller with 13 and 10 
EGF-like repeats for Lin-12 and Glp-1, respectively. The four mammalian Notch proteins 
are closely related to the Drosophila protein. Notch 1 and Notch2 contain 36 EGF-like 
repeats, whereas Notch3 has 34 EGF-like repeats and Notch4 has 29 EGF-like repeats. 
Notch receptors are proteolytically processed and glycosylated prior to expression on the 
cell surface in most systems (25). 
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The four characteristic regions within the intracellular domains of the Notch 
receptors each involve a different function for the receptor. The RAM domain is situated 
just past the transmembrane domain and before the ankyrin repeat region and was 
originally identified as a molecule that associates with the DNA-binding protein, RBPJk 
Figure 1. The Notch receptor has several distinct domains. 
During receptor maturation, cleavage at site SI generates two non-covalently 
associated subunits (NECD and NICD). The negative regulatory region (NRR), 
composed of three LIN12/Notch repeats (LNR) and the heterdimerization domain 
(HD) protect the Notch receptor from unregulated activation. Activation of the 
receptor occurs after ligand binding to the EGF-like repeats, resulting in S2 cleavage 
by ADAM-type metalloproteases. The third cleavage, S3, immediately follows and is 
mediated by y-secretase, which results in the release of the Notch intracellular domain 
(NICN) (26). 
(also referred to as CSL) (27). The domain consists of 100 amino acids and includes a 
NLS near its RBPJK binding domain. The RAM domains of all four mouse Notch 
receptors have been shown to be able to bind to RBPJK in vitro, which is important for its 
activity as a transcriptional co-activator of the HES and HRT family of transcription 
factors (28). The most highly conserved region of the Notch intracellular domain is the 
ankyrin repeat region and all Notch receptors contain 6-7 ankyrin repeats (29). It has 
been shown that a seventh ankyrin repeat is present in Drosophila Notch, which diverges 
from the consensus ankyrin repeat sequence (30). The ankyrin repeats are important for 
4 
Notch signaling by mediating protein-protein interactions, and mutations within this 
region repress receptor ability to activate downstream targets. Missense mutations in the 
first and second ankyrin repeats of mouse Notch 1 display loss of function phenotypes 
(31), and mutations within the ankyrin repeats of mouse Notch2 result in early embryonic 
lethality (32). Additionally, missense mutations within the ankyrin repeats of human 
Notch3 results in the condition known as CADASIL, a type of stroke associated with 
dementia (33). The ankyrin repeats of mammalian Notchl have also been shown to 
weakly associate with RBPJK and act as a weak transcriptional activation domain (34-
36). The C-terminus of the receptors contains a second NLS (except on Notch4) just past 
the ankyrin repeat region, a Transcriptional Activation Domain (TAD) found only in 
Notchl and Notch2, and a PEST sequence responsible for the high turnover rate of the 
Notch proteins (37). Expression of the intracellular domain of Notch has been shown to 
function as a constitutively active receptor by activating downstream target genes such as 
HES1 (38). This has been utilized to activate Notch signaling in the absence of ligand in 
gain-of-function studies, and it is a strategy used to understand differences between 
Notch receptors. 
1.2 The Notch ligands 
Notch receptors become activated upon binding to ligands expressed on 
neighboring cells. These ligands are part of the DSL family, named for Delta and Serrate 
from Drosophila and Lag-2 from C. elegans (39). Genetic and molecular studies first 
identified a family of structurally related ligands for the Drosophila Notch receptor and 
for the C.elegans Lin-12 and Glp-1 receptor proteins. These ligands, encoded by the 
Delta and Serrate genes in Drosophila (40) and by the lag-2 and apx-1 genes in C. 
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elegans (41-44), are all membrane-anchored extracellular proteins. There are seven 
known ligands in mammals, named Delta-like-1, -3, and -4 (Dill, D113, D114), Jagged -1 
and -2, F3/Contactin, and NB3. The extracellular domains of the DSL ligands contain a 
variable number of EGF-like repeats and a second cysteine-rich conserved motif, referred 
to as the DSL (Delta-Serrate-Lag-2) region (41, 43). Structural, expression, and 
functional analyses have identified vertebrate Notch ligands in Xenopus, mouse, rat, 
chicken, and humans (45). These vertebrate molecules have overall structures similar to 
Delta and Serrate, and all have extracellular regions with EGF-like repeats and the 
cysteine-rich DSL motif. The DSL region is important for ligand function, because point 
mutations that affect conserved cysteines in the Lag-2 DSL motif result in strong loss-of-
function phenotypes (41). In contrast, the intracellular domains of all the putative Notch 
ligands display no significant sequence similarity (41). Cell aggregation assays have 
shown that both Delta and Serrate bind to the extracellular EGF-like repeat region of 
Notch and that only two of the extracellular EGF-like repeats of Notch, namely repeats 
11 and 12, are necessary and sufficient for this interaction (46-48). There is a high degree 
of functional conservation in the ligand-binding properties of Notch proteins from 
different species (46-48). 
DSL ligands are also cleaved by Kuzbanian/TACE ADAM proteases (49) and 
ultimately are cleaved by y-secretase to liberate ligand ICD fragments that have 
transcriptional activation properties (50-52). 
6 
1.3 Notch gene and protein regulation 
1.3.1 Transcription, splicing and glycolsylation 
Notch receptor and ligand genes in mammals can undergo alternative 
transcriptional initiation or splicing to generate distinct protein isoforms. For example, 
Imatani and Callahan (53) have described an isoform of Notch4 expressed in breast 
cancer cell lines, which is transcribed from an alternative promoter. The predicted gene 
product from this mRNA codes for an N-terminally truncated Notch4 product, consisting 
of most of the intracellular domain. The D113 ligand gene can generate multiple protein 
isoforms through alternative splicing (54). The alternative isoforms vary at their extreme 
C termini. The Jagged2 gene is subject to alternative splicing whereby EGF-like repeat 6 
can be included, or not, depending on the presence of a specific in-frame exon. The 
extent to which alternative promoter usage and alternative splicing are used to generate 
multiple Notch receptors and ligands is not well understood and biological functions for 
each Notch4, D113, and Jagged2 isoform have yet to be determined. 
1.3.2 Proteolytic processing and (3-hydorxylation during synthesis 
Notch receptors are subject to proteolytic cleavage as they move through the 
secretory pathway (17) . The first cleavage occurs at cleavage site 1 (SI), between the 
LNR repeats and the transmembrane domain generating two polypeptides that remain 
associated through a noncovalent interaction requiring divalent cations (18). A furin-like 
convertase enzyme is responsible for this cleavage in mammalian tissue culture cells 
(19). Ligand-induced Notch signaling can occur in the absence of furin processing of 
Notch 1. Bush et al. (21) were able to show that interaction of ligands with the uncleaved 
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form of Notch 1 can block mouse C2C12 myoblast differentiation. Several additional 
Notch cleavages can occur to generate distinct receptors. For example, Notch proteins 
that have been cleaved within the EGF-like repeat containing domain and Notch proteins 
that have been cleaved to remove C-terminal sequences have been found (21, 55-57). The 
nature and function of alternative proteolytic processing of Notch is unclear. Many EGF-
repeats contain a consensus sequence for P-hydroxylation of aspartic acid and 
asparagines residues. Dinchuk et al. (58) generated aspartyl P-hydroxylase (BAH) mutant 
mice which had undetectable P-hydroxylation activity in liver preparations. They 
displayed phenotypes similar to Jagged2 loss-of-function mutants (58). Additionally, it 
was shown that Jagged proteins are subject to P-hydroxylation in tissue culture cells, 
suggesting that this modification plays a significant role in Notch activation, at least 
through alterations of Jagged2-Notch signaling. 
1.3.3 Degradation and receptor trafficking 
Several studies have demonstrated the importance of ubiquitination in the 
regulation of Notch signaling. The basic pathway starts with the ubiquitin-activating 
enzyme (El) which transfers ubiquitin, a 76 amino acid peptide, to an ubiquitin-
conjugating enzyme (E2). An E3 ubiquitin ligase combines with an E2 protein to transfer 
ubiquitin to a target substrate, or to the end of a polyubiquitin chain. As a consequence of 
this pathway, soluble target proteins are marked with ubiquitin for degradation in the 
proteasome. In addition, ubiquitination of transmembrane proteins at the plasma 
membrane targets them for endocytic internalization, whereas ubiquitination of 
transmembrane proteins in the sorting endosome targets them for degradation in the 
lysosome. There are seven classes of E3 ubiquitin ligase enzymes that have been 
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implicated in Notch signal transduction, or in regulation of the strength or duration of 
Notch signal transduction. These E3 proteins are Su(dx)/Itch, Deltex (DTX), Cbl, 
Neuralized, Mindbomb, Sel-10/Cdc-4 (a substrate recognition subunit in a multi-subunit 
E3 ligase), and Lnx. 
Su(dx)/Itch, a class E3 ligase, binds to the Notch ICD and ubiquitinates it. 
Su(dx)/Itch can transfer ubiquitin to Notch proteins that are still attached to the plasma 
membrane, and may therefore control the levels of Notch available for activation at the 
cell surface (59). 
Deltex (Dtx) proteins are ring-finger class E3 ligases, capable of self-
ubiquitination (60). In mammals there are four DTX proteins (DTX-1, -2, -25E, and -3) 
that influence myogenesis, neurogenesis, and lymphogenesis. The N terminus of DXT-1, 
DXT-2, and DXT-28E binds to the Ankryn/cdclO of NotchlCD, whereas this domain is 
missing in DXT-3. The role of Deltex (DTX) E3 ligase activity is unclear, since the ring-
finger motif is conserved in evolution but is not required for rescue of Deltex loss-of-
function phenotypes in flies. 
Cbl is an E3 ligase, most studied in the context of tyrosine kinase signaling. Jehn 
et al. (61) reported that when Notchl is phosphorylated on tyrosine residues in C2C12 
cells, it binds to c-Cbl, and that the tyrosine-phosphorylated form of Notchl accumulates 
when cells are treated with a lysosomal inhibitor. Thus, Cbl appears to target membrane-
bound Notch for destruction in the lysosome, at least in some cells where it is tyrosine-
phosphorylated. 
Neuralized and Mindbomb are unrelated and conserved ring-finger class E3 
ligases, which function to ubiquitinate the cytoplasmic domain of Delta-family ligands in 
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order to stimulate their endocytic internalization (62). This internalization of Delta, 
together with NECD, into signaling cells is required for activation of Notch receptors in 
neighboring signal-receiving cells. It is not understood why both Neuralized and 
Mindbomb have been conserved to perform the same or similar functions during Notch 
activation. 
Sel-10/Cdc-4 is a large multi-subunit E3 ligase known as SCF. Sel-10 binds to the 
PEST domain of a specific phosphorylated form of NotchlCD found in the nucleus, 
perhaps in complex with the negative feedback regulator Nrarp (63). Once bound, nuclear 
phospho-NotchlCD is ubiquitinated and targeted to the proteosome for degradation. The 
Sel-10 E3 ligase therefore functions to limit Notch-dependent transcriptional regulation 
after nuclear translocation of NotchlCD (64-66). The Sel-10 gene has recently been 
deleted from the mouse germline, and this causes a dramatic elevation of Notch4ICD 
without increasing expression of Notch 1, 2, or 3 ICDs (67). In 2001, Steve Reed's group 
found that Sel-10 also targets the cyclinE protein for ubiquitination, and therefore for 
proteolytic degradation (68) and that Sel-10 is a tumor-suppressor gene, mutated in the 
SUM149PT breast cancer cell line, and in a large number of endometrial carcinomas (68, 
69). 
Finally, LNX (ligand of Numb-protein X) is involved in regulating Notch 
signaling during asymmetric cell division. Numb is asymmetrically localized in sibling 
cells whose fate is decided by Notch signaling. McGill and McGlade (70) have shown 
that Numb interacts with Su(dx)/Itch, and suggested that Numb acts as an adaptor protein 
that recruits the Itch E3 ligase and the ubiquitination machinery for the ubiquitination of 
the NotchlCD complexed with Numb. LNX is an E3 ligase that targets Numb for 
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ubiquitination. Nie et al.(71) suggest that asymmetric distribution of LNX would 
establish an asymmetric distribution of Numb. It has been proposed that LNX augments 
Notch signaling by lowering the level of Numb in the daughter cell destined to respond to 
Notch signaling. 
1.4 Notch signaling 
1.4.1 Delta/Jagged activation of Notch signaling 
Canonical Notch signaling is tightly regulated by a series of proteolysis events. 
The activation of Notch receptors by Delta or Serrate ligands is a complex cell-cell 
communication event (72). In response to DSL ligand binding to Notch, two related 
events occur. The first is internalization of a ligand/NECD complex into the ligand 
expressing cell, and the second is cleavage of the Notch extracellular domain at cleavage 
site 2 (S2). Ligand binding to the EGF repeats 11 and 12 on the Notch extracellular 
domain (NECD) (73), results in a Notch receptor susceptible to cleavage by ADAM-type 
metalloproteases at site S2 (74). It has recently been shown that NECD first interacts with 
a DSL ligand resulting in dissociation and internalization of the NECD, and that this must 
occur before S2 cleavage (75). The highly related ADAM metalloproteases TACE and/or 
Kuzbanian are responsible for S2 cleavage. The S2 cleavage event targets a sequence just 
outside of the Notch transmembrane domain, and this leaves a membrane-spanning Notch 
protein fragment with a tiny remainder projecting into the extracellular space. This Notch 
receptor fragment is targeted for further proteolytic cleavage by a presenilin containing 
multisubunit protease commonly known as y-secretase. y-secretase cleaves Notch at 
cleavage site 3 (S3), near the C-terminal end of the transmembrane domain, thus 
releasing NotchlCD from its membrane tether (76). NotchlCD translocates into the 
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nucleus, where its RAM23 sequences bind to a transcriptional repressor complex through 
direct contact with the CSL (for CBF1, Suppressor of Hairless, or Lag-1) DNA-binding 
protein. NotchlCD/CSL interaction disrupts the transcriptional repressor complex sitting 
on DNA, recruits transcriptional activating proteins, and turns on transcription of genes 
that were repressed prior to Notch activation (72, 77). Much of what has been learned 
about Notch activation and regulation of transcription has been stimulated by the 
discovery of activated alleles of Notch receptors in cancer, including the discovery of 
activated Notch4 in mouse mammary tumor virus- (MMTV) induced breast cancer (78-
80). 
1.4.2 Other Notch ligands 
The structural properties of the extracellular domain of Notch receptor suggest 
that they may interact with other proteins besides the Delta and Serrate/Jagged ligands 
and Fringes. Extracellular calcium concentrations control the affinity of Notch 
ligand/Notch receptor interactions (81). This phenomenon is exploited to restrict Notch 
activation during early embryonic development. In a screen to identify Drosophila gene 
products with affinity for the NECD, a number of extracellular and cell surface proteins 
were found that can bind to Notch (82). Wingless (Wg), a Drosophila Wnt protein, was 
identified in this screen. Wg bound to a Notch protein lacking the first 18 EGF-like 
repeats, indicating that this protein interacts with Notch through a surface that is different 
from those used to bind DSL ligands. More recent data suggest that the Wingless-Notch 
interaction may activate alternative forms of signal transduction and play an important 
role in regulating developmental processes that are dependent on Delta/Serrate ligands 
and Wnt proteins (83). A novel Notch ligand, F3/Contactin, was shown to activate Notch 
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signaling in oligodendrocytes (84). This cell surface protein has six immunoglobulin-like 
domains followed by four fibronectin type-three domains and a GPI-link. F3/Contactin 
activates the disheveled-signaling pathway, a pathway distinct from that activated by 
Delta and Serrate family ligands (84). Finally, NB3, a member of the F3/contactin 
family, was found to be a ligand for the Notch 1 receptor during oligodendrogliogenesis 
via signaling through Deltexl (85). 
1.4.3 Gene targets of Notch signaling 
1.4.3.1 Direct targets of Notch are member of the HES and 
HRT gene families 
HES (Hairy-Enhancer of Split) and HRT (Hes related repressor protein; a.k.a. 
Hey, Hesr, and HERP) gene families encode basic helix-loop-helix (bHLH) proteins that 
are transcriptional repressors of gene expression, functioning downstream of Notch 
signaling. Their expression patterns in different tissues and during development are not 
completely overlapping. Hes has been shown to act as a transcriptional repressor by three 
different mechanisms. One of these occurs through formation of a complex with 
mammalian TLE/Grg (mammalian homologues of Groucho) corepressor proteins. This 
complex binds to E-box and/or N-box elements in responsive promoters (86). Another is 
through formation of nonfunctional heterodimers with bHLH transcription activating 
factors, such as MyoD and H/Mashl. A third, less characterized mechanism described for 
HES-1 requires its Orange or helix3-helix4 domain to repress transcription of its own 
promoter, as well as transcription of the p21waf promoter (87). HRT, in addition to 
passive repression of transcription by sequestration, can bind a heterologous set of 
corepressors, N-CoR/mSin3A/HDAC. For the six HES-family proteins and three HRT 
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proteins, only a limited number of target genes are known. For example, HES1 represses 
its own expression, as well as expression of H/Mash, CD4, and acid a-glucosidase, 
whereas HRT1 is known to repress its own promoter. 
1.4.3.2 Other known targets of Notch signaling 
In addition to members of the HES and HRT gene families, a number of genes 
directly implicated in cancer are known to be upregulated as a direct consequence of 
CSL-dependent Notch signaling. Chen et al. (88), while studying the transcriptional 
control of ErbB2, identified a palindrome binding protein, which was identical to CSL, 
that bound the ErbB2 promoter. In 293T tissue culture cells, Notch IICD and CSL 
cooperated to activate transcription from a wild-type, but not mutant, ErbB2 promoter. 
While studying the mechanism by which activated Notch 1 transforms HC11 mouse 
mammary epithelial cells, Dievant et al. were unable to detect upregulation of ErbB2 
gene expression (89), suggesting that regulation of ErbB2 by NotchlCD may depend on 
cell-type-specific transcription factor expression or be subject to regulation by other 
signaling pathways. 
Another gene whose expression is upregulated by CSL-dependent Notch 
signaling is cyclin Dl. Ronchini and Capobianco (90) have previously shown that 
Notch IICD activates transcription of the cyclin Dl gene and CDK2 activity with rapid 
kinetics in an ElA-immortalized baby rat kidney cell line (RKE). This resulted in 
stimulation of cell cycle progression from Gl to S-phase. Notch IICD mutations that were 
incapable of activating cyclinDl transcription failed to transform RKE cells, suggesting 
that NotchllCD transformation of RKE cells requires induction of cyclin Dl expression. 
This group also showed that CSL binds, in a DNA sequence specific manner, to the 
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cyclin Dl promoter, consistent with the idea that Notch 1ICD activates cyclin Dl 
transcription through the CSL-dependent signaling pathway. Interestingly, Notch 1ICD 
expression did not significantly increase DNA synthesis in 0.1% serum, indicating that 
induction of cyclin Dl expression and activation of CDK2 in RKE cells are not sufficient 
to induce proliferation or cellular transformation, and that other factors are required for 
oncogenic transformation by Notchl in this context. 
Notchl signaling in some contexts has been shown to induce Notch4, but not 
Notch2 or Notch3 expression (91). It is likely that this too is a consequence of CSL-
dependent signaling, since the Notch4 promoter contains a CSL-responsive element. 
NFKB2 gene is strongly repressed by CSL in the absence of Notch activation 
(92). Myc, p21 and p27 have also been shown to be targets of Notch signaling. 
The understanding of the role the Notch signaling pathway plays in normal 
development and tumorigenesis has been aided by the generation of Notch null and 
transgenic mice. A summary of these findings can be found in Table 2. 
1.5 Notch signaling in cancer 
1.5.1 Notch as a tumor promoter 
Aberrant Notch signaling has been shown to be oncogenic. This is mostly derived 
from studies demonstrating aberrant Notch ligand/receptor expression and tumor 
development. However these data do suggest a possible causative role for deregulated 
Notch signaling in tumor pathogenesis. 
The first study to identify a role for Notch signaling in tumor development, was 
the discovery that Czech II mice infected with mouse mammary tumor virus (MMTV) 
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developed mammary tumors (93, 94). Of the mammary tumors that developed in these 
mice, 18% (9 of 45 tumors) exhibited MMTV integration into the Notch4 locus. Of the 
tumors displaying MMTV integration into Notch4, all exhibited integration within a 
region of Notch4 that gives rise to a truncated protein consisting primarily of a 
constitutively active form encoding the transmembrane and intracellular domains. Similar 
to MMTV. 
In humans, aberrant Notch 1 expression has been identified as a causative factor in 
the development of T-cell acute lymphoblastic leukemia and lymphoma (T-ALL) (78). A 
chromosomal translocation, t(7;9)(q34:q34.3), juxtaposes the coding region of the C-
terminal domain of NOTCH1 adjacent to the T-cell receptor P-locus. This translocation 
results in the expression of a truncated constitutively active Notch 1 protein, commonly 
referred to as translocation-associated Notch 1 (TAN1) (78). 
1.5.2 Notch as a tumor suppressor 
In some contexts, Notch is a tumor suppressor. Conditional Notch 1 knockout 
mice develop cutaneous basal cell carcinoma-like lesions that have increased levels of 
Hedgehog and Wnt signaling (95), two pathways that are frequently dysregulated in 
human basal cell carcinoma. Transgenic mice expressing a dominant negative form of 
MAML1, a pan-Notch inhibitor, develop cutaneous squamous cell carcinomas that are 
also associated with Wnt pathway activation (96). Multiple different Notch receptors are 
expressed in the normal epidermis, suggesting that the global Notch inhibition results in 
this squamous phenotype. One Notch target gene that appears to contribute to its tumor 
suppressive effects in the epidermis is p21waf (97), an important regulator of cell cycle 
progression. In other contexts, Notch and Wnt display a positive interaction. However, in 
16 
this context p21wa represses Wnt4a expression and presumably Wnt signaling in normal 
epithelium (98). The basis for this tissue-specific negative interaction between Notch and 
Wnt is unknown; but it has been hypothesized that CSL only binds the p21waf promoter in 
particular cells (e.g. keratinocytes). Other work suggests that negative crosstalk between 
Notch and p63 (a factor implicated in the establishment of keratinocyte fate and 
keratinocyte self-renewal) regulates the balance between self-renewal and differentiation 
(99). Therefore dysregulation of this Notch function could also contribute to keratinocyte 
transformation. 
1.6 Notch in mammary gland development and cancer 
There are several possible roles for Notch in the development of the mammary 
gland, but not much is currently understood. From what is known about the function of 
Notch signaling in flies (77) and worms (100), a role for Notch signaling in 
epithelial/mesenchymal transitions, the regulation of mammary epithelial growth and 
branching during puberty (101), or cell-fate specification is possible. Notch signaling 
could also be involved in inductive interactions in the mammary gland (77, 102, 103). 
Notch signaling could regulate lactogenic differentiation (77, 104-106), cell proliferation 
(107, 108), stem cell self-renewal (109), or even apoptosis/involution (110). There are 
many documented biological functions for Notch signaling in both invertebrate and 
vertebrate systems and the most important roles in the mammary gland are still not fully 
understood. 
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allele 
Notch 1 null 
Notch 1 hypomorph 
(null generated by 
mutation in S3 
cleavage site) 
Notch2 hypomorph 
Notch2 (genreated by 
mutation in ankyrin 
repeat) 
Jaggedl null 
Jagged 1 null/Notch2 
null 
Hrtl null 
Hrt2null 
Hrtl/Hrt2 null 
MMTV-mN4ICD 
WAP-mN4ICD 
MMTV-mNlICD 
phenotype 
embryonic lethal by El 1.5; at E9 embryos were smaller, with 
distended pericardia and deficit in posterior development; 
somitogenesis is delayed and uncorrdinated 
embryonic lethal between E10 and El2; deficit in posterior 
development; expanded perciardial sac at E10.5; lack of 
vascular morphogenesis at E9.5 
50% of heterozygous Notch2 null emryos die perinatally from 
defects in glomerular development of kidney; defects in eye 
vasculature; heart defects (growth retardation, pericardial 
effusion, widespread hemorhagging) 
embryonic letal at El 1.5; no effect on somitogenesis; pycnosis 
in neuroepithlium of telenchepalon, cranial ganglia cells and 
optic and otic vessels 
emryonic lethal before El 1.5; hemorrhaging, lack of blood 
vessels in yolk sac at E10.5; eye defects; no defects in 
somitogenesis; 
characteristics of Alagille Syndrome; kidney defects; jaundice; 
growth retardation; paucity of intrahepatic bile ducts; heart 
defects; eye defects 
no pathology 
critical during heart development; ventricle septum defect; 
persistent foramen ovale; tricupsid valve stenosis; 
cardiomyopathy 
embryonic lethal by El 1.5; placental defects; defects of 
primitive vascular plexus in yolk sac by E10.5; vascular defects 
including hemorhagging and absence of large blood vessels. 
form poorly diffferentiated mammary and salivary 
adenocarcinomas; develop lactation deficient mammary glands; 
incomplete differentiation of the salivary glands, glands of the 
nasal mucosa and maxillary sinus, the extraorbital lacrimal 
glands, and the Harderian glands of juvenile and adult 
transgenic mice; male mice were sterile 
mammary ductal growth unaffected; pregnancy dependent 
growth and differentiation of secretory lobules inhibited; 
tumors in 100% by 25 weeks (70 weeks in virgin) 
impaired ductal and lobular-alveolar development; repressed b-
casein promoter; develop mammary tumors that are pregnancy 
and lactation independent; male mice do not form tumors 
reference 
( in) 
(112) 
(113) 
(32) 
(114) 
(115) 
(116) 
(117-119) 
(118) 
(80,120) 
(121) 
(122) 
Table 2. Notch transgenic and null mice reported in the literature. 
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1.6.1 Formation of the mammary gland 
In evolutionary terms the mammary gland is a rather young organ. It is thought to 
be derived from apocrine-like skin glands of synapsids, which probably served as a 
source of moisture for the parchment-shelled eggs and as a source of nutrients for the 
hatchlings (123). The origin of the gland in close association with feathers and hair is still 
reflected on a molecular level. A number of genes are expressed in hair, whiskers and 
feathers as well as in the mammary gland, and deletion of some genes affects 
development of all the epidermal appendages. Another common feature of all skin 
appendages is the dependence on reciprocal signals between the epithelium and the 
mesenchyme (124, 125). 
Mammary gland development is initiated during embryonic life. The first 
manifestation of the gland in many mammals is an elevated ridge or milk line, which then 
fragments into individual buds in specific regions lateral of the dorsal midline. These 
buds are either located in the thoracic region in primates, in the inguinal area in ungulates 
or along the entire length of the trunk in rodents and pigs. In the mouse embryo the first 
morphological signs of mammary rudiments are lens-like placodes that form around 
embryonic day 11 and protrude slightly from the body wall. Within 1 day these placodes 
grow into bulb-shaped buds that invaginate the underlying dermis. Growth of the buds is 
mainly achieved through cell migration from the epidermis. Rapid cell proliferation sets 
in on embryonic day 15 at the tip of the buds and leads to outgrowth of a primary sprout, 
which starts to elongate and bifurcate. These processes create a small ductal tree at birth 
that is connected to the skin and the outside through the nipple. This structure continues 
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to grow at the same pace as the animal until puberty, when hormone-dependent 
development and rapid ductal elongation and side branching begin. 
The surrounding mesenchyme participates in and is also altered in these 
processes. As soon as the epithelial bud forms, concentric layers of mesenchymal cells 
orient themselves like a dense halo around the epithelium. These so-called 'mammary 
mesenchyme' cells are induced by signals coming from the epithelial cells. When the 
primary sprout elongates, it pushes through this sheath of cells and grows into deeper 
layers of the dermis toward the presumptive fat pad, which forms the stroma of the adult 
organ. The mammary mesenchyme remains close to the epidermis and participates in the 
formation of the nipple. 
1.6.2 Evidence for a role for Notch in the mammary gland: studies 
using murine mammary cells and transgenic mice 
1.6.2.1 Mouse models reveal a role for Notch signaling: in the 
mammary gland: in vitro studies 
The HCll mouse mammary epithelial cell line (126) is a clonal derivative of the 
COMMA D cell line that was derived from normal pregnant, mid-gestation BALB/c 
mammary epithelium (127). HCll cells are not capable of anchorage-independent 
growth but have retained the capability to differentiate and express milk proteins in 
response to lactogenic hormones. Taking advantage of these properties, Robbins et al. 
(128) and Dievart et al. (89) showed that expression of Notch4ICD and NotchllCD, 
respectively, in these cells conferred the capability for anchorage-independent growth in 
soft agar. Thus, expression of NotchlCD blocks the ability of HCll cells to differentiate 
and confers on them growth properties associated with malignant transformation. 
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TAC-2 is a second mouse mammary epithelial cell line that has been useful for 
studying the effect of Notch4ICD signaling on normal epithelial architecture. These cells 
have the ability to form well-polarized histotypic structures when grown in collagen gels 
(129). When treated with hepatocyte growth factor (HGF) they form branching tubules 
in culture. Uyttendaele et al. (130) have shown that Notch4ICD expression inhibits tubule 
formation by TAC-2 cells. Soriano et al. (131) showed that Notch4ICD signaling blocks 
the formation of glucocorticoid-induced alveolar-like structures in TAC-2 cells grown in 
collagen gels and causes loss of contact inhibition in TAC-2 cells grown on collagen-
coated dishes. 
It has been shown that transgenic mice that overexpress cyclin Dl in the 
mammary epithelium develop mammary hyperplasias and subsequent mammary tumors 
(132). At the present time it is not known which of the Notch gene(s) normally affect 
cyclin Dl expression in the mammary gland. The context in which cyclin Dl expression 
is being evaluated may be an important factor in interpreting results. However, in the 
HCll mammary epithelial cell line, which is frequently used to study the effects of 
oncogene expression on cell growth and differentiation, overexpression of cyclin Dl 
causes inhibition of cell cycle progression and suppression of cell growth (133). In 
addition, overexpression of cyclin Dl in HC11 cells induces differentiation as defined by 
increased p-casein expression. 
1.6.2.2 Mouse models of Notch signaling in the mammary 
gland: in vivo studies 
Activation of Notch signaling in mammary carcinoma has been well studied in 
mouse models. Activation of Notchl, Notch3, or Notch4 in mouse mammary epithelial 
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cells blocks mammary gland development and leads to mammary tumorigenesis (80, 
120, 122.). Activated Notch2 in normal mammary epithelial cells in vivo has not been 
reported. 
Two transgenic mouse strains have been developed which express the Notch4ICD 
from either the MMTV LTR or the whey acidic protein (WAP) promoter (80, 120, 121, 
134). The common phenotype in these strains is that 100% of females are blocked in their 
ability to lactate, and all develop mammary tumors. In virgin females containing the 
MMTV LTR-Notch4ICD transgene, there is minimal ductal development in the 
mammary gland. After the first pregnancy, ducts do fill the mammary fat pad, but there is 
little lobular development or cellular differentiation. In contrast, WAP-Notch4ICD 
females exhibit normal ductal development, but during pregnancy secretory lobular 
development is severely impaired. Reciprocal transplantation studies of mammary 
epithelium from females of each of the transgenic strains with normal FVB/N 
demonstrated that transgenic mammary epithelium was unable either to grow in 
epithelium-divested FVB/N mammary fat pads from virgin mice (from MMTV LTR-
Notch4ICD), or to functionally differentiate in epithelium-divested FVB/N mammary fat 
pads from parous mice (from WAP-Notch4ICD). In contrast, FVB/N mammary 
epithelium was able to grow and differentiate in epithelium divested transgenic mammary 
fat pads. Coincident with limited lobular development of the WAP-Notch4ICD mammary 
gland during pregnancy, dysplastic lesions appear throughout the gland that do not 
regress after weaning and progress to frank carcinoma. Immunohistochemical analysis of 
this tissue indicates that WAP-Notch4ICD mammary tumors originate from secretory 
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epithelial cell progenitors, whereas the MMTV LTR-Notch4ICD tumors appear early and 
arise from ductal progenitor cells or from individual epithelial stem cells. 
Similar phenotypes were observed in mice expressing murine NotchllCD and 
Notch3ICD. Transgenic mice expressing these receptors developed lactation independent 
mammary tumors with several differentiation defects in the mammary gland. The 
mammary tumor phenotype induced by NotchllCD or Notch3ICD transgenic mice is 
very similar to the phenotype reported in MMTV-int3/Notch4ICD transgenic mice (80). 
In both cases, the mammary tumors are diverse and develop at different stages of 
differentiation. However, one important difference should be noted: whereas mammary 
tumors develop in both male and female MMTV-Notch4ICD transgenic mice, (80) 
mammary tumors in males of the MMTV-NotchllCD or MMTV-Notch3ICD mice did 
not develop. 
1.6.3 Cross-talk between the Notch pathway and other signaling 
pathways in the mammary gland 
Uyttendaele et al.(130, 135) have presented evidence for negative cross-talk 
between the Wnt-1 and Notch4 signaling pathways in the TAC-2 mammary epithelial cell 
line suspended in collagen gels. In this setting Wntl, like HGF and TGF-02, induces 
branching morphogenesis by TAC-2 cells. TAC-2 cells expressing Notch4ICD did not 
respond to HGF or to TGF-P2, but underwent branching morphogenesis in the presence 
of Wnt-1, suggesting that Wntl signaling is dominant to Notch4ICD signaling in TAC-2 
cells in the branching morphogenesis assay. Deletion analysis of Notch4ICD 
demonstrated that the RAM23 and Ankryn/cdclO repeats are required for inhibition of 
ductal morphogenesis. 
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1.6.4 Evidence for a role for Notch in the mammary gland: studies in 
human breast cancer 
In human breast cancer, the role of Notch is still unclear, but activated Notch 
signaling may be a common event during tumorigenesis. Notch 1, Notch4, and Jagged 1 
are increased in human breast cancer tissue (136, 137), and high expression of Jagged 1 
and Notch 1 correlated to poor patient survival (137), suggesting that levels of Notch 
signaling components may serve as prognostic markers of disease. In many ways, it is 
also very difficult to address the role, or potential role(s), played by Notch signaling in 
human breast cancer with the current state of knowledge. Expression analysis of the 
levels of Notch receptors, ligands, or Fringes and whether the expression correlates with 
specific pathological or clinical features is sparse. Studies are primarily limited to in situ 
hybridization analysis performed on human breast tumor specimens (137). These data 
have revealed that all four Notch receptors, four Notch ligands, and one of three Fringes 
are expressed at varying frequencies within this collection of tumors. For example, 
Notch3 is expressed in approximately half of the tumors and highly expressed in three 
tumors. Notch3 is very highly expressed in vessels that have been recruited to many of 
the tumors, suggesting that this receptor may play an important role in breast tumor 
angiogenesis. One of the biggest challenges to assessing the role of Notch signaling in 
human breast cancer is the heterogeneity of this disease and a large collection of tumors 
must be studied to establish any correlation between the Notch system expression profile 
and tumor pathology or outcomes. Despite these challenges, preliminary data indicate 
that Notch receptors, ligands, and Fringes are expressed in human breast cancers and 
supporting stromal elements, including tumor vessels. Studies on Notch 1ICD and 
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Notch4ICD in mammary epithelial cell transformation have been extremely informative 
and have guided understanding of oncogenic Notch signaling. It will also be important to 
keep in mind the recent finding that Notch genes can function to suppress tumor growth 
(138). 
Additionally, in breast cancer, Notch2 expression has conversely been correlated 
to better survival in patients, with expression associated with well differentiated tumors 
(139). 
1.6.5 The role of Notch in mammary stem cell renewal and 
differentiation 
Stem cells in adult tissues are characterized by their ability to undergo self-
renewal and multilineage differentiation (140). In the steady state, these divisions are 
asymmetric in which a stem cell is able to produce an exact copy of itself as well as a 
daughter cell that undergoes differentiation into the lineages found in differentiated 
tissues. The elucidation of pathways that govern stem cell functions is essential for 
understanding normal development and organogenesis. Moreover, there is increasing 
evidence that defects in these pathways play an important role in carcinogenesis (141). 
The isolation of stem cells from the mammary gland in humans and rodents has been 
hindered by the lack of identified specific cell surface markers. Furthermore, 
investigation of the mechanisms underlying cell-fate decisions in mammary 
stem/progenitor cells has been limited by the lack of suitable in vitro culture systems, 
which maintain these cells in an undifferentiated state (142). 
The concept that cancer might arise from a rare population of cells with stem cell 
properties was proposed about 150 years ago (143). There are several reasons why the 
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concept that cancers arise from the transformation of stem cells is an area of active 
research. Stem cells are long-lived and subject to the accumulation of multiple mutations 
that are a prerequisite for carcinogenesis. For example, women exposed to atomic bomb 
radiation in Hiroshima and Nagasaki developed breast cancer approximately 20 to 30 
years after exposure and mutations found in these women's breast cancers are consistent 
with those known to be induced by radiation (144). Additionally, women exposed to 
radiation during late adolescence had the highest susceptibility to breast cancer 
development concomitant with the period when the mammary gland has the highest 
number of stem cells (140). Further evidence that stem cells may play a role in 
carcinogenesis is the observation that normal stem cells and cancer cells share several 
important properties. These include 1) the capacity for self-renewal, 2) the ability to 
differentiate, 3) active telomerase expression, 4) activation of antiapoptotic pathways, 5) 
increased membrane transporter activity, and 6) the ability to migrate and metastasize. 
Properties, such as anchorage independence, which have been thought to be a hallmark of 
transformed cells, have recently been described as a property of normal tissue stem cells 
(145-147). One of the key early events in transformation may be the dysregulation of the 
normally highly regulated process of self-renewal. Stem cells are the only cells capable of 
undergoing self-renewal divisions. 
Recently, Dontu et al. (148) have described a role for Notch in the maintenance of 
mammary gland stem cells. They propose that in the mammary gland, as has been 
reported in other developmental systems, Notch activation acts as a regulator of 
asymmetric cell-fate decisions. Notch activation promotes self-renewal in stem cells, 
whereas in later stages of development it biases cell-fate decisions in mammary 
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progenitor cells towards adoption of a myoepithelial cell fate versus an epithelial cell 
fate. This may explain the observation that the percentage of breast cancer incidence 
increases with age, as stem cells within the mammary gland have acquired multiple 
mutations and become transformed. 
1.7 Notch signaling in tumor angiogenesis 
Notch has important roles in normal arteriogenesis and neo-angiogenesis, both of 
which are likely to be recapitulated in cancers (149). In some instances, Notch signaling 
in endothelial cells appears to be triggered by ligands expressed on tumor cells (150), 
which might contribute to the aggressive clinical behavior of tumors expressing high 
levels of Notch ligands (137, 151, 152). Solid tumors (and stem cell niches) are I0W-O2 
tension environments. Recent studies suggest the existence of an intimate and 
functionally important interaction between Notch and hypoxia-inducible factor (HIF)-la, 
a transcription factor that regulates many genes involved in the response to hypoxia, 
including factors that promote angiogenesis. Expression of HIF-la and Notch 1 are 
correlated in breast cancer, in which Notch 1 appears to upregulate HIF-la expression 
(153). Other recent data suggest that HIF-la binds and stabilizes activated Notchl, 
leading to enhanced Notch signaling (154). 
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2. OUTLINE OF THE STUDY 
Notch signaling functions as an oncogene or tumor inhibitor in various cancers. 
The study presented in this thesis was performed to characterize the consequence of 
Notch signaling in human breast cancer. The hypothesis that activation of the different 
Notch receptors correlates to different outcomes was tested by activating signaling and 
inhibiting receptor expression in the human mammary tumor cell line, MDA-MB-231. 
Specific Aim 1: To characterize the consequences of Notch signaling in mammary 
tumor cell proliferation, apoptosis, and survival. 
Specific Aim 2: To determine the role of Notch signaling in the angiogenic response 
of human mammary tumors. 
These approaches led to the identification that Notch2 activation in an estrogen 
negative, highly invasive breast tumor line results in tumor inhibition, while Notch4 
activation results in an increased oncogenic response. Additionally, it was discovered 
that while Notch2 activation suppresses tumor growth in vivo, the angiogenic response by 
the host to the tumor remains robust, comparable to the highly aggressive Notch4ICD 
tumors. This study provides new insight into the consequences of Notch receptor 
signaling in human breast cancer and addresses future models. 
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3. MATERIALS AND METHODS 
3.1 Human mammary normal and tumor cell culture 
Commonly used human mammary tumor lines and one normal mammary cell line 
were utilized for this study. All lines were obtained from ATCC. The MCF10A (CRL-
10317) cells were grown in DMEM/F12 supplemented with 5% horse serum, lOOng/ml 
cholera toxin, 50ng/mL EGF, lOug/mL insulin, and 5ug/mL hydrocortisone. BT474 
(HTB-20) and MCF-7 (HTB-22) cells were grown in Eagle's MEM supplemented with 
10% FBS and lO^g/mL insulin. ZR75-1 cells (CRL-1500) were grown in RPMI 
supplemented with 10% FBS. MDA-MB-468 (HTB-132) cells were grown in Leibovitz's 
L-15 medium supplemented with 10% FBS. The MDA-MB-231 cell line was obtained 
from ATCC (HTB-26), and grown in Earle's aMEM with glutamine and nucleosides 
(Cellgro) supplemented with 10% FBS, 1% nonessential amino acids (Gibco) and 
50ug/mL gentamicin reagent solution (Gibco). All cells were grown in a humidified, 
37°C incubator in the presence of 5% carbon dioxide, except the MDA-MB-468 cell line, 
which was grown in 100% air (0% CO2). At confluence, all cells were subcultured at a 
1:4 ratio. Table 2 summarizes the major characteristics of these cells. 
3.2 Preparation of adenovirus 
Adenoviral vectors were made by cloning hNotch2, mNotch4, HRT1, HRT2 and 
GFP into a pAdLox cDNA vector. pAdLox DNA vectors were cut with Sfil in order to 
linearize the plasmid to increase transfection efficiency. 2jag of linear plasmid was 
transfected into Cre-8 cells. The media was changed 24 hr post-transfection and comet 
formation was observed over a 7-10 day period. Adenovirus was collected and purified 
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using a cesium chloride gradient. Concentration was determined in viral particles per mL 
(vp/mL) by reading the OD at 260nm and 280nm and calculated by; OD260nm * 10 
(Dilution Factor) * 1.1X1012. Purity of the virus was determined by the ratio of 260/280 
and fell within the appropriate range (1.17-1.35). 
Cell Line 
ZR75-1 
MCF-7 
MB-MDA-468 
MB-MDA-231 
MCF10A 
Origin/ 
Tumorgenicity 
Infiltrating ductal 
carcinoma, ascites/ 
+ 
Breast 
adenocarcinoma, 
pleural effusion/ 
+ 
Metastatic 
adenocarcinoma, 
pleural effusion/ 
+ 
Breast 
adenocarcinoma, 
pleural effusion/ 
+ (metastatic) 
Basal/myoepithelial 
derived/ 
ER 
+ 
+ 
-
-
-
E-
cadherin 
+ 
+ 
+ 
-
-
Vimentin 
-
-
-
+ 
-
p53 
Wild-type 
Wild-type 
Mutant 
Mutant 
Wild-type 
Her2/ 
neu 
-
-
+ 
-
-
Table 3. Properties of mammary cell lines used in this study. 
Human mammary tumor lines and one non-transformed line were utilized in this study. 
ER= estrogen receptor. 
3.3 Preparation of retrovirus 
Producing recombinant virus from a plasmid involves plasmid transfection into 
the retroviral packaging cells. 293GPG (155) cells are a 293-derived retroviral packaging 
cell line capable of producing high titers of recombinant virus particles. These cells are 
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grown in DMEM with 10% FBS, 10-ug/mL tetracycline, 2ug/mL puromycin, and 
300ng/mL G418 (293GPG growth medium). Twenty-four hours prior to transfection, 
293GPG cells were plated into 10cm culture dishes to be 70-80% confluent the following 
day. The day of transfection, 293GPG growth medium was removed, cells were washed 
gently with PBS once, and lOmLs of fresh DMEM with 10% FBS was added. 10-20ug of 
plasmid was transfected using 2.5ul GeneJuice/1 \ig DNA. The next day, transfection 
medium was removed and lOmls of fresh DMEM with 10% FBS was added. Retroviral 
medium was collected 72 hours or 96 hours following transfection, and filtered through a 
0.45 um filter. Virus was used immediately, stored at 4°C for up to one week, or at -80°C 
for longer periods. Immediate use generated the highest transfection efficiency. 
3.4 Transfections and transductions of expression constructs 
Stable expression of Notch intracellular domain expression constructs was 
achieved by transfecting 3-8ug of vector using GeneJuice (Novagen) at a 2.5uL/ug DNA 
ratio in 10cm dishes. All transfections were done in serum-free medium for 6 hours at 
which time transfection solution was replaced with normal growth medium. Cells were 
selected with appropriate resistance antibiotic (200ng/mL Zeocin (Invitrogen) for 
Notch IICD and Notch2ICD plasmids, and 200ng/mL hygromycin B (Invitrogen) for 
mNotch4ICD) until all cells in negative control were dead. At this point, cells were 
maintatined in maintenance medium (50ug/mL Zeocin and 50|ig/mL hygromycin B). 
Transient expression of NotchlCD constructs was achieved by adenoviral infection. Cells 
were infected with adenoviral constructs at either 200pfu/cell or optimized viral 
particle/cell. Infections were performed in serum free medium with 5ul GeneJuice per 
lOOOOvp, for 1 - 6 hours. For knockdown experiments, shRNA retroviral vectors 
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targeting Notch2 or a non-targeting vector for control were obtained from 
OpenBiosystems (V2HS135987). Negative control for transfection was achieved by 
using the shRNA non-silencing control vector (RHS1707), which contains no homology 
to known mammalian genes. Cells were infected in 10cm dishes with lOmL of retroviral 
infection medium and lOug/mL polybrene for 12 hours. Infection medium was replaced 
with normal growth medium for 24 hours and then selection medium containing 
0.75ug/mL puromycin selection antibiotic was added. Cells were changed over to 
mainteneance medium of 0.33ug/mL puromycin when all cells in negative control were 
dead. 
3.5 NotchlCD reporter constructs and luciferase assays 
To evaluate Notch receptor signaling capability CBF1, HESl, Hrtl and Hrt2 
luciferase reporter constructs were utilized. The CBF-1 luciferase construct contains 6 
repeats of the CBF-1 binding sequence. The HESl, HRTl, and HRT2 utilized promoter 
sequences. For assays, cells were plated at 180,000 cells/well in 12-well plates. The 
following day, cells were transfected with lOOng reporter construct and 20ng CMV-
Renilla using transfection procedure as described. 24 or 48 hours post-transfection cells 
were analyzed for reporter activity using the Promega Dual Luciferase kit. Experimental 
points were performed in triplicate, and all experiments performed at least 3 times. Data 
expressed are mean +/- SD. 
3.6 RNA isolation, RT-PCR and qPCR 
Total RNA was collected using TRI-Reagent (Sigma) following the 
manufacturers protocol. RNA was DNAse treated and reverse transcribed using oligodT 
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and random hexamers in the presence of AMV reverse transcriptase (Promega) to make 
cDNA. Successful cDNA production was verified using primers against GAPDH or beta-
actin. The resulting cDNAs were used for PCR and quantitative PCR analysis. RT-PCR 
performed on tumor sample for angiogenic cytokines were from pooled populations. 
qPCR analysis was done by using the iCycler apparatus (Bio-Rad) and the SYBR Green 
PCR Core Reagents system (Qiagen). Results were evaluated with ICYCLER IQ real-
time detection system software (Bio-Rad). Samples were run in triplicate, and all 
quantifications were normalized to endogenous control beta-actin. Data shown are 
relative expression ratios of target genes. Primer sequences are listed in Table 4. 
3.7 Immunoblotting 
Cells were lysed with HNTG (20mM HEPES, pH 7.4, 150mM NaCl, 10% 
Glycerol, 1% Triton X-100, 1.5mM MgC12, l.OmM EDTA, Protease Inhibitor Cocktail 
(Roche), 200uM NaV04, 1 mM NaF, 5 mM P-glycerol phosphate) buffer and cleared of 
insoluble material by centrifugation for 10 minutes at 14,000 rpm at 4°C. Protein 
concentration was deterined by BSA method, and lOOug of protein loaded. Lysates were 
subjected to SDS-polyacrylamide gel electrophoresis followed by electrophoretic transfer 
to nitrocellulose (Schleicher & Schuell) and immunoblotting with the indicated 
antibodies. The following antibodies were used for immunoblot analysis: anti-Notchl 
(l(ig/mL), anti-Notch2 (l(j.g/mL), anti-Notch4 (0.4ug/mL) and anti-Jagged 1 (0.2jj.g/mL) 
(Santa Cruz), anti-phospho Akt (Cell Signaling, 1:1000), anti-phospho-Erk (Sigma, 
1:10,000), total Akt ( Cell Signaling, 1:1000), Cyclin D3 (1:1000, Cell Signaling) and 
p21 (Cell Signaling, 1:1000). Following incubation with HRP-conjugated secondary 
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Table 4. PCR Primer sets for Notch receptor and angiogenic cytokine expression 
Gene 
Cyclophilin 
(m) 
Cyclophilin 
(h) 
P-actin (h) 
Notch 1 (m/h) 
Notch2 (m/h) 
Notch3 (m/h) 
Notch4 (m) 
HES1 (h) 
Hrtl (h) 
Hrt2 (h) 
VEGF-A (m) 
VEGF-A (h) 
VEGF-B (m) 
VEGF-B (h) 
VEGF-C (m) 
VEGF-C (h) 
VEGF-D (m) 
VEGF-D (h) 
VEGFR1 (m) 
VEGFR1 (h) 
Forward Primer (5'-3') 
AGCTAGACTTGAAGGGGAATG 
CTCGAATAAGTTTGACTTGTGT 
TT 
AGAAAATCTGGCACCACACC 
CTGGGTAGCCATGGGGTGACT 
C 
CACAGAGGCTGGGAAAGGATG 
ATA 
CCTAGCCCAGCCACTGCCACT 
G 
GCTCTAGAGCTGTGGACCTGA 
TGGG GTGACA 
CTAAACTCCCCAACCCACCT 
CGTCGGGATCGGATAAATAA 
CGTCGGGATCGGATAAATAA 
CAGAAGGAGAGCAGAAGTCC 
AAGGAGGAGGGCAGAATCAT 
CCCAGTTTGATGGCCCCA 
CCCAGCCTGATGCCCCTG 
GTAAAAACAAACTTTTCCCTAA 
TTC 
AACAAACTCTTCCCCAGCCA 
GCAAGACGAGACTCCACTGC 
GCAGGAGGAAAATCCACTTG 
TCAGCAGCTCAAGTGTCACC 
CCAGCAGCGAAAGCTTTGCG 
Reverse Primer (5'-3') 
ATTTCTTTTGACTTGCGG 
GC 
CTAGGCATGGGAGGGAAC 
A 
GTCTCAAACATGATCTGG 
G 
TGGACCACTTTGCCAACC 
GGGACAT 
GGCCACCTGAAGGGAAGC 
ACATA 
GTCATGCCTGTGTACTAG 
GTAC 
GGGGTACCCCCTAGTTCA 
GATTTCTTA CAACCGA 
AGGCGCAATCCAATATGA 
AC 
GCACTCTCGGAATCCTAT 
GC 
GCACTCTCGGAATCCTAT 
GC 
CTCCAGGGCTTCATCGTT 
A 
CCAGGCCCTCGTCATTG 
TGCCCATGAGTTCCATGC 
TGCCCATGAGCTCCACAG 
TTTAAGGAAGCACTTCTG 
TGTGT 
TTTAACAAGCATTTCTGTG 
GAC 
GGTGCTGAATGAGATCTC 
CC 
GGGTGCTGGATTAGATCT 
TTG 
GCTGCTTGGAGATCTCAC 
TG 
CTCCTTGTAGAAACCGTC 
AG 
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VEGFR2 (m) 
VEGFR2 (h) 
VEGFR3 (m) 
VEGFR3 (h) 
NRP-1 (m) 
NRP-1 (h) 
NRP-2 (m) 
NRP-2 (h) 
ANG-1 (m) 
ANG-1 (h) 
TIE-1 (m) 
TIE-1 (h) 
FGF-2 (m) 
FGF-2 (h) 
P1GF (m) 
P1GF (h) 
ATGACATCTTGATTGTGGCAT 
ATGACATTTTGATCATGGAGC 
GCAGGAGGAGGAAGAGGAGC 
TGCAAGAGGAAGAGGAGGTCT 
CCCTGAGAGAGCCACACACA 
CCCGAGAGAGCCACTCATG 
AACTGCAACTTTGATTTTCCG 
CAATTGCAACTTCGATTTCCTC 
AGCTACCAACAACAACAGCA 
AGCTACCACCAACAACAGTG 
CCCCACTGGTCTCCTTTAG 
CCCCGCTGGTCTCGTTCTC 
CCCGACGGCCGCGTGGAT 
CCCGACGGCCGAGTTGAC 
ATGCAGATCTTGAAGATTCCC 
TGCAGCTCCTAAAGATCCGT 
TTCCAGATGCTGGGCAAG 
TC 
CCCAGATGCCGTGCATGA 
G 
TGCATGCTGGGTGGACTA 
TCA 
CAGGCTTGGCGGGCTGTC 
C 
CGTCACACTCATGCACTG 
G 
GTCATCACATTCATCCAC 
CAA 
TGTTCTGTCATTGGGGTT 
AGC 
CCGGTCGTTTGGGCTGGA 
GCAAAGGCTGATAAGGTT 
ATGA 
CAAAGATTGACAAGGTTG 
TGG 
AATGGCAGACCAGGCAAT 
C 
CACAATGGTCGACCAGTC 
C 
ACTTAGAAGCCAGCAGCC 
G 
CACATTTAGAAGCCAGTA 
ATCT 
CTCTTCCCCTTGGTTTTCC 
T 
GGGAACAGCATCGCCGCA 
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antibodies (Bio-Rad), bound antibodies were visualized by chemiluminescence (West 
Pico SuperSignal, Pierce). 
3.8 Immunohistochemistry 
Immunostaining for the V5 and HA epitope tags was performed using an anti-V5 
antibody (Invitrogen) at a 1:200 dilution, or an anti-HA antibody (Covance) at a 1:50 
dilution. This was followed by a biotinylated secondary antibody, the ABC reagent 
(Vector Laboratories) and diaminobenzidine as the color substrate. BrdU immunostaining 
was performed using a monoclonal anti-BrdU antibody (MP Biomedicals). Following 
fixation, cells were treated with 0.3% hydrogen peroxide (tumors with 3%) in methanol 
at room temperature for 20 minutes, followed by treatment with 20|ig/mL proteinase K in 
50mM TRIS/5nM EDTA for 7 minutes at room temperature. Immediately following 
proteinase K treatment, cells were washed in 0.4% glycine/PBS, and then incubated in 
1.5N HC1 for 15 minutes at 37°C. Cells were then washed in 0.1M Borax buffer and 
immunostained with a 1:100 dilution anti-BrdU, followed by a biotinylated anti-mouse 
antibody, and the ABC reagent. The antigen was detected using diaminobenzidine as the 
color substrate. DNA fragmentation was labeled with biotin dUTP using terminal 
deoxynucleotidyl transferase (TdT). Following 3% (for tumor sections) or 0.3% (for 
cells) hydrogen peroxide treatment and proteinase K antigen retrieval, cells or sections 
were incubated for 1 hour at 37°C in TdT reaction solution (TdT 0.25units/nl, Biotin-
dUTP 0.4nmol/ml in TdT Buffer (30mM Tris-base pH=7.2, 140mM sodium cacodylate, 
ImM cobalt chloride). Incubation in TdT Reaction Termination Buffer (300mM NaCl, 
30mM sodium citrate) quenched TdT activity. Antigen was detected using the ABC Elite 
reagent and diaminobenzidine as the color substrate. Immunostaining for endothelial cells 
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was performed with both anti-PECAM antibodies (BD Biosciences) and the anti-
endothelial antigen MECA-32 (BD Biosciences) with similar results. For anti-PECAM 
staining, staining was performed with a biotinyltyramide amplification reagent 
(PerkinElmer), using diaminobenzidine as the color substrate. Immunostaining with anti-
mouse MECA-32 and LYVE-1 (R&D Systems) was performed as described above for 
the V5 epitope tag. 
3.9 Growth curves, clonal growth and soft agar analysis 
For growth curves, cells were plated in complete medium at a concentration of 
15,000-30,000 cells/cm2 in 24 well plates, and counted on day one and then every other 
day after plating using a Coulter Counter. Growth curves were performed with each 
group measured in quadruplicate, with two counts performed in each well. For 
assessment of proliferation, cells were incubated in lOmM BrdU for 4 hours before 
fixation in 4% paraformaldehyde and immunostaining. Data shown are representative 
data collected from a minimum of three independent repeats of each experiment. For 
clonal growth experiments, cells were plated by serial diltution at 100 and 50 cells/well in 
all 6 wells of a 6-well plate. Two weeks later, cells were washed 2 times with PBS, fixed 
with methanol, and stained for 10 minutes with toluidine blue (Sigma). Using Scion 
Image analysis software, a picture of each individual well was taken, and number of 
colonies counted and total area covered by colonies calculated. Shown are representative 
data collected from three independent experiments. For soft agar assays, a layer of 4mLs 
0.8% low melting temperature (LMT) agarose (SeaKem) dissolved in MDA-MB-231 
growth medium was put into 60mm dishes and then overlaid with a suspension of cells in 
6mls 0.4% LMT agarose. After 21 days, the dishes were stained with O.lmg/mL of p-
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iodonitrotetrazolium (Sigma) in PBS overnight. The next day, the colonies were counted 
using a dissecting microscope and pictures taken with a Zeiss AxioCam camera. 
3.10 Flow Cytometry 
For 7-AAD incorporation, cells were collected by trypsinization, quenched with 
serum, and washed four times with PBS by spinning for 5 minutes at 800g. After the final 
wash, 70% ice-cold ethanol was slowly added dropwise to the cells. Fixed cells were 
stored at 4°C overnight. On the day of staining, cells were washed three times with PBS, 
and 1 mg/mL 7-AAD added immediately before analysis. 
3.11 Enzyme linked immunosorbent assay 
Detection of human angiogenic factors in cells and mice with MDA-MB-231 
tumors was performed using the TransSignal Angiogenesis Antibody Array (Panomics) 
following the manufacturer's instructions. MDA-MB-231 cells were cultured for 24 
hours in serum-free medium, medium collected, filtered to remove cellular debris, and 
2mLs undiluted media immediately used for the assay. For comparison of secreted 
angiogenesis factors from tumors, blood was collected from mice by eyebleed into 
EDTA-coated microcontainers (Becton Dickinson), plasma separated by centrifugation at 
2000g for 10 minutes at room temperature, and samples were stored at -20°C until use. 
3.12 Quantification of BrdU labeled and TUNEL labeled cells in vitro and in 
tumor sections. 
For cells plated onto coverslips and immunostained for BrdU or TUNEL, ten 
random fields were captured for each sample, and the percentage BrdU-labeled or 
TUNEL-labeled cells determined by counts of labeled/total cells were collected in a 
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blinded manner. For tumor sections, ten to thirty random fields were captured for two 
sections per tumor. BrdU-labeled and TUNEL-labeled cells were counted, and total 
positive cells/field was calculated. 
3.13 Tumor xenograft growth in vivo 
All protocols involving mice were evaluated and approved by our Institutional 
Animal Care and Use Committee, and performed under veterinary supervision. NCr 
homozygous nude mice (Taconic) at 5-6 weeks of age were injected subcutaneously in 
the right flank with 2.5xl06 stably transfected MDA-MB-231 populations. For the 
mammary fat pad model, 4.0xl06 stably trasnfected MDA-MB-231 populations were 
injected into the mammary fat pad with Matrigel (Sigma). For the mammary fat pad 
model using MCF-7 cells, mice were first ovariectomized and implanted with an estrogen 
pellet (Transduction Laboratories). One week after implanting of pellet, mice were 
injected into the mammary fat pad at nipple #2 with 5x106 cells in Matrigel. Tumor 
growth was monitored by palpation, and the onset noted when tumors were palpable. 
Tumor size was measured with calipers, and tumor volume calculated using the 
calculation: 
Volume = (4/3) x l l x (shorter width)/2 x (shorter width)/2 x(longer width)/2 
Representative data were obtained from 5 mice/experimental group, and the entire 
experiment was repeated in three independent trials. Prior to collection, mice were 
injected intraperitoneally with 200|j.l of 80mM BrdU solution at 15hr and lhr before 
collection. Individual tumors were split for fixation in 4% paraformaldehyde and flash 
freezing in liquid nitrogen, and used for histology and immunostaining, or RNA and 
protein collection, respectively. 
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3.14 Ovariectomization and implantation of estrogen pellet 
Before injection of estrogen-dependent MCF-7 tumor cells, mice were first 
ovariectomized and implanted with a time release estrogen pellet. Mice were 
anesthesized with 250mg/kg Avertin, and one small incision made above the spine. The 
peritoneum was cut to access the ovary. The ovary was gently pulled out of the cavity, 
the bursa cut, and the ovary completely removed. After the second ovary was removed 
the incision was closed with a staple after a time release estrogen pellet (0.36mg f3-
estradiol, Transduction Laboratories) was inserted just beneath the skin. 
3.15 Quantification of vessel area in tumor sections 
Non-counterstained PECAM sections (five tumors per condition) were quantified 
for vessel area. Four to five pictures of comparable regions of each tumor were taken and 
quantified in a blinded fashion. In Photoshop 7.0, the vessels were outlined in a 
transparent layer and filled in with black. The outlined vessel image was opened in Scion 
Image, converted to binary, thresholded, and area of black pixels measured. Shown is 
average percentage of vessel area per tumor area, and results were analyzed by Student's 
t test to determine statistical significance. 
3.16 Mouse tumor angiography for observation of tumor vessels. 
For tumor angiography, vasodilation buffer (PBS with 4mg/L papaverin and lg/L 
adenosine) was infused into the left ventricle. Immediately following vasodilation, 
fixation was performed with 2% paraformaldehyde/1% glutaraldehyde in PBS. After 
flushing with PBS to clear fixation solution, bismuth contrast agent mixed 1:1 with 10% 
gelatin/PBS was injected at 0.2mL/10g body weight. The animal was immediately 
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covered in ice to harden the contrast agent and X-rays taken using a specimen 
radiography system at 25kV, 3.25mA for 15-30 seconds (Faxitron) and developed using 
Kodak mammography film. 
3.17 Microarray Analysis from Meta Analysis of ONCOMINE Database. 
The expression of Notch2 transcript in human breast tumor tissues was compared 
using the ONCOMINE meta-analysis of cancer gene microarray meta-analysis public 
database (156). Student's t-test was used for used for analyzing differences between 
published datasets on the database. 
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4. RESULTS 
4.1 Development of a mammary adenocarcinoma model to evaluate Notch 
signaling 
To determine how Notch activation influences mammary tumor phenotype, 
MDA-MB-231 cell lines were generated to express the constitutively active receptors 
(NotchlCD). Previous studies suggested expression of Notch in the MDA-MB-231 cells 
(53), and detectable protein levels of Notchl, Notch2, Notch4, and the Jaggedl ligand 
were observed (not shown). MDA-MB-231 cells were additionally chosen as the cell 
model since they are a human metastatic mammary carcinoma derived cell line (157) and 
can form tumors in nude mice. This implication that Notch signaling may be abnormally 
active in MDA-MB-231 cells would additionally allow for loss of function studies using 
reagents to inhibit endogenous Notch signaling. To establish a gain-of- function model, 
stable populations of hNotchl, hNotch2 or mNotch4 pathways were generated. To verify 
stable integration of the tagged NICD, transcripts were detected by RT-PCR utilizing the 
epitope tag, demonstrating stable populations of cells expressing the NICD had been 
made (Figure 2A). However, while mNotch4ICD-HA protein was readily detectable in 
T24 cells by immunostaining (Figure 2B) and MDA-MB-231 cells by western blotting 
(Figure 2C), confirmation of protein for the hNotchlICD-V5 and hNotch2ICD-V5 
populations was unsuccessful. Because the transcript was present in these populations, it 
was thought that the protein levels may be undetectable due to the high turnover of the 
receptor. Therefore, adenoviral constructs were utilized to express the protein in 
concentrations to be detectable by immunostaining and western blotting methods. MDA-
MB-231 cells were transduced with LacZ, hNotchlICD-V5, hNotch2ICD-V5, and 
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Figure 2. Transcript and protein detection of NotchlCD constructs in MDA-MB-231 
and T24 cells. 
To verify production of transfected NotchlCD constructs, RT-PCR, 
immunohistochemistry, and western blotting was performed. A) RT-PCR for tagged 
constructs in the MDA-MB-231 stable populations (50ng of plasmid was used as positive 
control). Forward primer (FP) designates primer within the Notch 1, Notch2 or Notch4 
gene, reverse primer (RP) designates primer for the V5 or HA epitope tag (see Table 4 in 
Materials and Methods). GAPDH verified cDNA production. B) Immunostaining for the 
HA tag in T24 bladder carcinoma cells stably expressing the HA tag. C) MDA-MB-231 
cells stably expressing mNotch4ICD-HA were subjected to SDS-PAGE and western 
blotting for the HA epitope tag. D) Immunostaining for the V5 and HA tag in MDA-
MB-231 cells transduced with NotchlCD adenoviral vectors confirmed presence of 
tagged constructs. E) MDA-MMB-231 cells transduced with adenoviral vectors were 
subjected to SDS-PAGE and western blotting for V5. Lanes 1, 3, 5, 7, 9, 11: lysates 
immunoprecipitated with V5. Lanes 2, 4, 6, 8, 10, 12: whole cell lysates. Lane 1-2) LacZ, 
3-4) mN4ECD, 5-6) hN2ICD, 7-8) hN2ECD, 9-10) hNHCD, 11-12) hNlECD. 
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mNotch4ICD-HA adenoviral vectors and immunostaining performed for the V5 and HA 
tag. For both the hNotchlICD-V5 and mNotch4ICD-HA staining, nuclear accumulation 
was observed, as well as cytoplasmic staining (Figure 2D). However, for the 
hNotch2ICD-V5 cells, only nuclear localization was observed (Figure ID). Furthermore, 
MDA-MB-231 cells were transduced with LacZ control, mNotch4ECD, hNotch2ICD, 
hNotch2ECD, hNotchllCD and hNotchlECD at a 200pfu/cell concentration. Lysates 
were collected and subjected to immunoprecipitation with anti-V5 antibody (Invitrogen). 
mNotch4ECD (~170kDa), hNotch2ICD (llOKDa), hNotchllCD (120kDa), 
hNotchlECD (~240kDa) proteins were readily identified in transduced cell lysates by 
western blotting for V5 epitope (Figure 2E). No detection of hNotch2ECD was observed. 
Interestingly, immunprecipitating for the tagged protein resulted in decreased signal. 
Functional receptor activity was tested in two ways. The first utilized real time 
PCR to detect changes in transcript levels of the Notch effectors HESl and HRTl. The 
second method used to verify functionality of signaling was to analyze activity of CBF1, 
HESl, and HRTl response elements. No differences were observed in the cell 
populations by real time PCR in HESl transcript levels (Figure 3A). However HRTl 
transcript showed high expression in all populations with the exception of hNotch2ICD 
cells (Figure 3A). 
Luciferase response elements were used to detect possible variation in ability of 
NICD to activate CBF1, HESl and HRTl promoter elements. A low level of CBF1-
luciferase reporter activation was observed in the MBA-MB-231 cells, as expected due to 
the presence of endogenous Notch ligand/receptors. All stable populations activated 
CBF1 reporter activity, with hNotchllCD showing a 5.5-fold increase (p=0.05), 
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hNotch2ICD an 8-fold increase (p=0.05) and mNotch4ICD a 2.5-fold increase (Figure 
2A) after normalizing to control (empty vector, pcDNA3.1 or pcDNA4V5). HES1 
reporter was additionally activated in all of the NICD populations. hNotchllCD showed a 
5.5-fold increase (p=0.01), hNotch2ICD a 2-fold increase (p=0.05) and mNotch4ICD a 
3.9-fold increase (p=0.05) over control (Figure 3B). Finally, HRT1 activity showed an 
8.3-fold increase in hNotchlICD-V5 (p<0.05), hNotch2ICD-V5 less than 0.05-fold 
increase (p=0.05), and mNotch4ICD-HA a 3.7-fold increase (p=0.05) (Figure 3B). 
Although no differences in HES transcript were observed by the stable NICD 
populations, differences in HRT1 were detectable. Additionally, increases in both CBF1 
luciferase activity, and HES1 and HRT1 promoter activity could be detected. These 
collective data demonstrate that Notch signaling can be amplified in the MDA-MB-231 
cells, and that stable expression of hNotchlCD, hNotch2ICD and mNotch4ICD lead to 
increased levels of CBF1 reporter. 
4.2 Notch regulation of the malignant phenotype of MDA-MB-231 cells in 
vitro 
4.2.1 Proliferation studies 
The effect of activating the Notch 1, Notch2 and Notch4 pathways in the MDA-
MB-23 1 cells was first investigated by looking at changes in proliferation. Growth curve 
analysis revealed that mNotch4ICD cells grew more rapidly and at peak growth, to a 2-
fold higher cell density than control (300,000 cells/cm2) (Figure 4A). Conversely, cells 
expressing hNotch2ICD had decreased rates of growth, with 2.6-fold reduction in cell 
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Figure 3. Modulation of Notch signaling in MDA-MB-231 cells. 
A) Stable cell populations were assessed for Notch activation using CBF-1, HES1, and 
HRT1 luciferase reporter constructs. These constructs and the Renilla reporter were 
transiently transfected into MDA-MB-231 cells and collected after 48 hours for 
luciferase assay. Luciferase readings were normalized to Renilla values, and shown are 
average data from four experiments with triplicate samples. D) Stable cell populations 
were tested for transcript levels of HES1 and HRT1 by real time PCR. Shown are 
averages of three independent stable populations. 
number (115,000 cells/cm ) at peak cell density compared with mNotch4ICD (Figure 
4A). hNotchllCD cells demonstrated a slight growth advantage over control, with cell 
numbers reaching to 200,000 cells/cm2 at peak growth, compared to control, which 
reached a peak density of 150,000 cells/cm2 (Figure 4A). To confirm the growth 
properties seen in the mNotch4ICD and hNotchllCD populations was attributed to 
increased cell proliferation, percentage of cells in each population in S-phase was 
calculated by BrdU incorporation. The increase in the amount of S-phase cells in the 
mNotch4ICD cells correlated with the growth curve as this population had 1.5-fold as 
many S-phase cells than control cells (p<0.05), and 2-fold as many labeled cells 
compared to Notch2ICD (p<0.05) (Figure 4B and C). The amount of S-phase cells in the 
hNotchllCD population was no different than control. 
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Cell cycle analysis by incorporation of 7-AAD was then used to analyze the cell 
cycle phases in the hNotch2ICD, mNotch4ICD and hNotch2ICD/mNotch4ICD stable 
populations (Figure 5A). The amount of S-phase cells in the mNotch4ICD population 
was similar to that found by BrdU immunostaining and quantitation, with 55% of 
mNotch4ICD cells in S-phase by incorporation of 7-AAD. However, by this analysis, the 
percentage of S-phase cells in hNotch2ICD (45%) was larger than control (39%). Both of 
these values were much higher than those calculated by BrdU immunostaining 
quantitation. However, this may be due to the sensitivity of 7AAD incorporation. When 
cells were pulsed for 30 minutes with BrdU and subsequently analyzed by flow 
cytometry using a FITC-BrdU antibody, 100% of cells had incorporated BrdU (not 
shown). For immunohistochemistry cells were pulsed with BrdU for 30 minutes, 
therefore sensitivity to antibody may be a contributing factor to differences observed 
between flow cytometry and immunohistochemistry. 
To determine whether Notch2 activity could inhibit the cell cycle progression of 
Notch4ICD cells observed by growth curve and cell cycle analysis, MDA- MB-231 cells 
stably expressing mNotch4ICD were transfected with hNotch2ICD to generate a stable 
population of hNotch2ICD + mNotch4ICD co-expressing cells. When Notch2ICD and 
mNotch4ICD were co-expressed, the percentage of S-phase cells was similar to 
hNotch2ICD (45%), with a dramatic increase in percentage of cells in G2 was (26.32%) 
(Figure 5A). 
47 
Figure 4. NotchlCD activation results in distinct proliferation characteristics. 
MDA-MB-231 stable NotchlCD populations were tested for proliferation by 
growth curve analysis and BrdU immunohistochemistry. A) Cells were plated at 
15,000 cells/well in a 24-well plate, and counted in quadruplicate every other day, 
starting at day 1. Shown is a representative experiment done in triplicate. B) Stable 
populations of MDA-MB-231 NICD lines were pulsed with lOuM BrdU for 30 
minutes, then fixed, probed with anti-BrdU, and visualized with the ABC 
amplification and DAB reagent as described in Materials and Methods. Shown are 
representative pictures. C) Labelled BrdU cells from MDA-MB-231 NICD 
populations were quantitated in a blinded fashion. Ten pictures of each sample 
were taken and total cells and BrdU positive cells were counted. Shown are 
percentage of positive BrdU cells in each population. 
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Figure 5. NotchlCD affects proliferation and cell cycle components in MDA-MB-
231 cells. 
A) Cell cycle analysis of hN2ICD, mN4ICD, and hN2ICD plus mN4ICD was done 
by incorporation of 7-AAD. Shown are percentages of cells in S, G2, and Gl phases. 
B) MDA-MB-231 cells were transduced with hN2ICD, mN4ICD, Hrtl, Hrt2, and 
GFP at 2000vp/cell. Lysates were collected and subjected to SDS-PAGE and western 
blotting for CyclinD3, phosphor-Erkl/2, and the V5, HA, and Flag tags. C) Stable 
populations of the MDA-MB-231 cells expressing N2ICD and mN4ICD were probed 
for p21 levels by western blot. 
Finally, analysis of cell cycle proteins was performed using both stable and 
transient expression of Notch2ICD and mNotch4ICD. Transient expression of 
Notch2ICD, mNotch4ICD, Hrtl and Hrt2 increased levels of CyclinD3, which were not 
detectable in control. However, no differences in pERK levels were observed in any of 
the groups (Figure 5B). p21waf expression was checked in stable populations by western 
blotting, and observed in the hNotch2ICD group, which was absent in mNotch4ICD 
(Figure 5C). Thus, in the MDA-MB-231 cells, it appears that p21waf may be repressed by 
mNotch4ICD, corresponding to increased cell cycle transit. 
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4.2.2 Survival Studies 
The decreased numbers of cells in the growth curve analysis of hNotch2ICD 
overexpressing cells could not be completely attributed to differences in cell cycle 
progression. Therefore an analysis of cell survival was performed. A characteristic of a 
malignant cell is its ability to grow independently of extracellular signals and matrix 
interactions, and survival at clonal densities or under anchorage independent conditions 
was tested. It has been demonstrated that activated Notch differentially affects ability to 
grow on attached substrata versus anchorage independent growth (91). In soft agar 
assays, the mNotch4ICD cells demonstrated an increased ability to grow, with a 2.8-fold 
higher average number of colonies than control (p<0.001, Figure 6A and B). 
Conversely, the hNotch2ICD cells were inhibited in the formation of colonies, 
with over a 3-fold decrease compared to control (p<0.05, Figure 7A and B). Similar to 
proliferation characteristics, no changes in the ability of hNotchllCD cells to grow in soft 
agar were observed (Figure 7 and B). Populations were then tested for ability to grow a 
clonal density. Sparsely plated cells expressing mNotch4ICD did demonstrate increased 
survival capability, showing increased colony number (2.3-fold, p<0.0001, Figure 7A) as 
well as growth area (3-fold, p<0.01, not shown) when compared to control. Conversely, 
activation with hNotch2ICD resulted in decreased colony number (2-fold, p=0.05, Figure 
7A) and decreased growth area (2-fold, p=0.05, not shown) compared to control. To 
determine if the MDA-MB-231 cells expressing hNotch2ICD were inhibited in growth 
and survival because of the lack of survival factors such as VEGF, and FGF, the levels of 
secreted angiogenic factors in the conditioned medium were determined. Surprisingly, all 
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Figure 6. NotchlCD affects MDA-MB-231 anchorage independent growth. 
MDA-MB-231 stable NotchlCD populations were tested for ability to grow in soft agar. 
A) A layer of 4mls 0.8% low melting temperature (LMT) agarose (SeaKem) dissolved 
in MDA-MB-231 growth medium was put into 60mm dishes and then overlaid with a 
suspension of cells in 6mls 0.4% LMT agarose. After 21 days, the dishes were stained 
with O.lmg/mL of p-iodonitrotetrazolium (Sigma) in PBS overnight. The next day, the 
colonies were counted using a dissecting microscope and pictures taken with a Zeiss 
AxioCam camera. B) Ten random fields were taken in a blinded fasion, and average 
number of colonies per field calculated. Shown are average number of colonies per field 
from two experiments. 
the cells expressing activated forms of Notch demonstrated higher levels of several 
factors (Figure 7B). These factors included vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), interleukin-la, and FGF-1. Adding conditioned medium 
from hNotch2ICD or mNotch4ICD populations to MDA-MB-231 parental or empty 
vector control cells showed no difference in cell growth rates as observed by growth 
curve analysis (not shown). Levels of Akt phosphorylation were analyzed by western 
blot, and it was found that when Notch2 was activated in the MB-231 cells, Akt was 
phosphorylated, which was not observed in the control or mNotch4 populations, or when 
Notch2 was coexpressed with mNotch4 (Figure 7C). 
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Figure 7. MDA-MB-231 stable populations have different survival characteristics. 
A) Stably transfected cell populations were plated at clonal growth density at 50 
cells/well in a 6 well plate. After two weeks in culture, cells were fixed in methanol and 
stained with toluidine blue. Shown are representative wells from each group and the 
quantitation of average number of colonies/well. Graphed are means ± SEM. 
Notch2ICD had significantly fewer colonies, and Notch4ICD significantly more 
colonies compared to vector transfected controls. B) Conditioned medium from stable 
cell populations and assayed by ELISA for levels of the cytokines indicated. C) Cell 
lysates of transduced cells were prepared for immunoblot analysis to detect p-Akt. 
4.2.3. Analysis of cell death 
TUNEL labeling was utilized to look at cell death. Immunostaining for TUNEL 
positive cells demonstrated hNotch2ICD cells had 2.5 fold increase in apoptotic cells 
(p<0.05, Figure 8D) compared to control cells. Flow cytometry using a FITC-TUNEL 
additionally showed an increase in TUNEL positive cells in the N2ICD population 
compared to control (Figure 8A). There was no significant difference in cell death in the 
mNotch4ICD cell populations compared to control (Figure 8B). When hNotch2ICD and 
mNotch4ICD were co-expressed, similar death observed with hNotch2ICD cells was 
observed (Figure 8C). 
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4.2.4 Notch2 inhibition in MDA-MB-231 cells affects proliferation, but 
not cell death 
Stable populations of cells with -50% inhibition of Notch2 transcript were 
generated for further study (Figure 9A). Growth curve analysis of MB-231 cells with 
Notch2 knockdown demonstrated an increase in cell numbers compared to control 
(Figure 9B). When endogenous Notch2 levels were decreased using shRNA, the 
percentage of cells in S-phase looked similar to mN4ICD results. Knockdown resulted in 
50.17% and 49.43% of cells in S-phase in populationl and population2 cell lines (Figure 
8C). Additonally, no changes in apoptosis were seen by TUNEL flow cytometry 
compared to control non-targeting population (Figure 9D). 
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Figure 8. NotchlCD affects cell death in MDA-MB-231 stable transfectants. 
Cells were used for TUNEL labeling to detect apoptotic cells by flow cytometry (A-
C). Cells were fixed in ice-cold ethanol, and end-labeling of nicked DNA was 
performed using the Cell Death Detection Kit. D) Additionally, TUNEL labeling was 
performed by immunostaining. Cells were stained, and quantified. 
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Figure 9. Notch2 inhibition affects cell proliferation but not apoptosis in MDA-
MB-231 cells. 
A) Cells were treated with shRNA to target Notch2 sequences, or treated with a non-
targeting control. Stable populations were generated with reduced Notch2 
transcripts. B) Cells stably expressing hNotch2ICD or mNotch4ICD were analyzed 
in a growth curve assay. Cells were plated in 24 well plates at 15,800 cells/cm2. At 
days indicated after plating, cells were trypsinized and counted. Values graphed are 
the average of quadruplicates. C) 7AAD incorporation was utilized for cell cycle 
analysis of stable populations. Shown are percentages of cells in S, G2, and Gl 
phases. D) Cells were used for TUNEL labeling to detect apoptotic cells by flow 
cytometry. The control in (D) is the non-targeting control population. 
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4.3 Notch regulation of the malignant phenotype of MDA-MB-231 cells in 
vivo 
4.3.1 Activation of hNotch2 inhibits MDA-MB-231 subcutaneous 
tumor xenograft growth 
Based on the in vitro results, it was hypothesized that the increased apoptosis and 
decreased survival of hNotch2ICD cells would correspond to impaired growth in vivo. A 
xenograft model of subcutaneous injection of tumor cells into nu/nu mice was utilized to 
directly assess if distinct tumor growth differences were apparent in the cells expressing 
the NotchlCDs. Our first observation was that while the control and the mNotch4ICD 
animals all formed tumors (100% tumor growth), mice injected with hNotchllCD and 
hNotch2ICD had a much lower proportion of tumor take, with 42% of the animals 
generating tumors. Even up to 4 months after injection, those animals with unsuccessful 
xenografts did not develop tumors. Secondly, the growth rate and final size of the tumors 
in each population was quite distinct (Figure 10B-E). MDA-MB-231 control cells formed 
significant tumors over the course of 30-40 days, while the tumors that did develop from 
hNotch2ICD cells were about 4-fold decreased in size (Figure 10A). Conversely, the 
activation of Notch4 led to highly accelerated tumor growth, with ~3 fold increase in 
tumor size in the same amount of time. Even though an end-stage analysis (at 44 days 
after injection) cannot reflect tumor cell behavior during the course of xenograft growth, 
we analyzed BrdU incorporation and TUNEL labeling to quantify proliferation and 
apoptosis at the end of the experiment. The mNotch4ICD tumors did have a higher rate of 
proliferation (Figure 11A), and the level of apoptosis measured by TUNEL labeling 
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Figure 10. Activation of influences tumor take and tumor growth in 
xenografts. 
MDA-MB-231 cells stably expressing control vector, hNotchllCD, hNotch2ICD, 
or mNotch4ICD were grown as xenografts in athymic nu/nu mice. A) The length 
and width of the tumors was measured at days indicated, and volumes calculated. 
Shown is the quantitation of three independent experiments (total n=15/group), 
and the corresponding ANOVA P-value. B-E) Control (B) and mNotch4ICD cells 
(E) showed 100% tumor penetrance, while the hNotchllCD (C) and hNotch2ICD 
(D) cells led to tumors in approximately 40% of the mice. Shown are 
representative mice from each group. 
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(Figure 1 IB) corresponded to the tumor size: few TUNEL positive cells in the 
hNotch2ICD tumors, and abundant TUNEL positive cells in the mNotch4ICD tumors, 
likely due to their large size. 
4.3.1.1 Pathological features of NotchlCD xenografts 
Tumors were collected for histological analysis and immunostaining. 
Corresponding to their growth characteristics, the control, hNotchllCD and hNotch2ICD 
tumors had necrotic central regions that were filled with inflammatory cells and regions 
of hemorrhage (Figure 12). Similar features were rare in mNotch4ICD tumors, which had 
a high level of cell density in the periphery and the core of the tumor. Trichrome staining 
also demonstrated that hNotch2ICD tumors were fibrotic and had a strong stromal 
reaction in the tumor, with regions between tumor lobes of highly organized vascular 
networks and fibroblast infiltration. On the other hand, the mNotch4ICD tumors were 
more encapsulated and dense, with less apparent collagen content compared to the 
control tumors (Figure 13). Trichrome staining of tumors additionally showed differences 
in tumor pathology. Within Notch2ICD tumors were fibrotic, with increased trichrome 
staining of the surrounding tumor, suggesting an activated fibroblast phenotype (Figure 
13). Moreover, mNotch4ICD tumors did not demonstrate this, and were more 
encapsulated compared to control tumors. These results potentially suggest that Notch2 
activation in MDA-MB-231 tumor cells results in an endothelium that is activated to 
recruit endothelial cells and activate the fibroblasts surrounding the tumor during growth. 
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Figure 11. NotchlCD xenografts have differences in apoptosis and proliferation in 
and end-point analysis. 
MDA-MB-231 NotchlCD cells were grown as subcutaneous xenografts in nu/nu mice. 
The 24 hours and 12 hours before tumor collection, 80uM BrdU. At collection, tumors 
were fixed in 4% paraformaldehyde and processed for paraffin embedding and 
sectioning. A) Cell proliferation was assessed by BrdU incorporation at the end of the 
experiment, and apoptosis measured by TUNEL labeling (B). 
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Figure 12. Tumor phenotype of NotchlCD xenografts. 
Tumor sections were stained with hematoxylin/eosin. For each tumor, representative 
fields from the tumor periphery (panels A, C, E, G) or the core of the tumor (panels B, 
D, F, H) are shown. Of note, although the Notch4ICD tumors are significantly larger 
than all other groups, those tumors displayed the highest cell density within all areas of 
the tumor, and had little necrosis (G-H). Conversely, the all other tumors had necrotic 
cores, and in particular, Notch 1ICD tumors had areas of necrosis close to the tumor 
periphery (panel C). Scale bar equals 100|uim. 
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4.3.1.2 Notch2ICD and mNotch4ICD tumors have increased 
vascularization 
In vitro, the MDA-MB-231 cells expressing activated forms of the Notch 
receptors secreted increased levels of survival/angiogenic factors. Therefore, to further 
investigate the ability of these tumors to recruit vessels, markers of blood endothelial 
(PECAM, MECA-32) and lymphatic endothelial (LYVE-1) cells were used to analyze 
tumor vascularization (Figure 14). The lymphendothelial marker LYVE-1 was used in 
conjunction with the blood vessel marker MECA-32 to differentiate between lymphatic 
vessels and blood vessels. Specific staining of blood vessels was observed in the MECA-
32 stained vessels, as adjoining tumor cell-filled lymphatic vessels were not positive 
(Figure 14A, black arrows). Conversely, LYVE-1 specificity for lymphatic vessels was 
determined, as adjoining vessels containing blood cells were not positive (Figure 14B, 
white arrows). There was a marked increase in the area of lymphatic vessels within the 
tumor in the hNotch2ICD (2-fold, p<0.05) and mNotch4ICD tumors (1.7-fold, p<0.001) 
compared with control tumors (Figure 15A). Interestingly, the hNotchllCD tumors 
contained no lymphatic vessels (Figure 15A). Blood vessels of the mNotch4ICD tumors 
were typically found clustered in "hotspots" along the perimeter of the tumors, while 
vessels of hNotch2ICD tumors were present throughout the tissue. Additionally the 
lymphatic vessels of both mNotch4ICD and hNotch2ICD tumors were larger with tumor 
cells completely filling the vessels, in comparison to the blood vessels, which were 
smaller in diameter and only containing blood cells, inflammatory cells, and few tumor 
61 
Figure 13. Stromal phenotype of NotchlCD xenografts. 
Collagen deposition within the tumor and tumor storma characteristics were 
observed with Trichrome staining. For each tumor, representative fields from the 
tumor periphery (panels A, C, E, G) or the core of the tumor (panels B, D, F, H) are 
shown. Control tumors (A and B) did show evidence of some collagen within the 
tumor, and signs of an activated fibroblast surrounding the encapsulated tumor. 
Notch IICD (C and D) and Notch4ICD (G and H) demonstrated little collagen 
deposition within the tumor. Conversely, the hNotch2ICD tumors (E and F) were 
fibrotic, with large amount sof collagen deposition within the tumor, and evidence 
of an activated stroma.. Scale bar equals lOOum. 
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cells. The overall extent of vascularization was the same between the 
hNotch2ICD and mNotch4ICD tumors. Using PECAM to quantify blood vessels it was 
found that Notch2ICD and mNotch4ICD had an equal area of vascularization per tumor 
area with 1.9-fold (pO.OOOl) and a 2.3-fold (p<0.0001) increase, respectively, in blood 
vessel area compared with control tumors (Figure 15A). hNotchllCD tumors had no 
differences in vascularization compared to control (Figure 15A). 
The differences in vascularization between tumor groups suggested the possibility 
that secretion of angiogenic factors by the tumor/host may provide a mechanistic basis 
for this variation. Using an ELISA-based assay to detect secreted angiogenic factors by 
Notch 1ICD, Notch2ICD and Notch4ICD expressing tumors in vivo, plasma from tumor-
bearing mice was collected at several time points during the course of the experiment 
(before inoculation with tumor cells, day 14, day 28, and day 44) and used to determine 
the release of human angiogenic factors from the tumors. The highest levels of 
angiogenic factors over the course of the experiments was observed on day 28, and mice 
with Notch2ICD and Notch4ICD tumors expressed more angiogenic factors than the 
NotchllCD and control tumors, in particular HGF and FGF-1 (Figure 15B). 
To further investigate differences in factors regulating angiogenesis/lymphangiogenesis, 
a panel of mouse- or human-specific RT-PCR primers were generated to identify 
cytokines from the human tumor or mouse stroma (Table 4). This analysis was done 
using RNA collected from tumors at the end of the experiment. In terms of tumor-derived 
transcripts (human primers), Notch4ICD tumors selectively expressed vascular 
endothelial growth factor-C (VEGF-C), neuropilin-1 (NRP-1) and placental growth factor 
(P1GF), but, unlike the rest of the tumors, did not express fibroblast growth factor-1 
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(FGF-1). Additionally, Notch2ICD tumors had lower levels of transcripts for 
angiopoietin-1 (Ang-1), and VEGF-D compared to control, and both Notch IICD tumors 
and Notch2ICD tumors had significantly lower neuropilin-2 (NRP-2) expression 
compared with control and Notch4ICD tumors (Figure 15C). Analysis was also 
performed with mouse-specific primers to detect host-derived cytokines. No detection of 
mouse VEGF-A, -B, or -C was detected in any of the tumors, however Notch4ICD 
tumors selectively contained mouse VEGF-D transcript. Additionally, VEGFR3, and 
NRP-1 both were expressed in the NotchllCD, Notch2ICD, and Notch4ICD tumors, and 
were absent in controls (Figure 15D). 
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Figure 14. NotchlCD tumors have different patterns of vascularization. 
MECA-32 (panels A, C, E, G, I) and LYVE-1 (panels B, D, F, H, J) staining 
was used to determine the presence of blood and lymphatic vessels within tumor 
sections. As shown in serial sections (panels A-B), these two antibodies showed 
a non-overlapping pattern of staining, with MECA-32 recognizing red blood 
cell-filled blood vessels that are not stained with anti-LYVE-1 (white arrows). 
Conversely, lymphatic vessels (L) were stained prominently with anti-LYVE-1, 
but not MECA-32 (black arrowheads). Tumor cells were found frequently 
within lymphatic vessels. Sections were counterstained with hematoxylin. Scale 
bar equals 50u.m in panels A and B and lOOum in panels C-J. 
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Figure 15. NotchlCD differerentially regulate tumor vascularization and 
angiogenic cytokine production. 
A) MDA-MB-231 tumors stably expressing NotchlCD were collected, fixed, and 
stained using PEC AM (black bars) to detect blood vessels and LYVE-1 (white bars) to 
detect lymphatic vessels. The percentage of area covered with vessels in each case was 
quantified and shown are means ± SEM. Both Notch2ICD and Notch4ICD tumors 
show an increase in tumor vascularization. B) Analysis of secreted circulating 
angiogenic factors in tumor-bearing mice was performed using an ELISA-based assay. 
Equal amounts of protein were added to the blots for each condition, and shown are 
representative data from plasma taken 28 days after tumor cell injection. RT-PCR was 
used to determine transcript levels of angiogenic cytokines in the tumors. Primers were 
designed to specifically detect tumor-derived human (C) versus host-derived mouse 
transcripts (D). 
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4.3.2 Activation of hNotch2 inhibits MDA-MB-231 mammary fat pad 
growth in vivo 
Tumor site has been well demonstrated to show that microenvironmental factors 
influence tumor growth, affecting rates of growth differently dependent on location. This 
was recently demonstrated for mammary xenografts in particular (158). Therefore it was 
determined if the phenotypes observed in the subcutaneous model of xenograft growth 
could be conferred to growth in the mammary fat pad. For this study, hNotch4ICD stable 
populations were included, and protein production verified by western blot. Previous 
experimental analysis in the subcutaneous environment demonstrated that hNotch4ICD 
activation resulted in no growth differences compared to control (not shown). Consistent 
with subcutaneous growth, Notch2 activated tumor cells were growth inhibited in the 
mammary fat pad, while the mNotch4 activated cells promoted tumor growth (Figure 16). 
hNotchllCD cells did not demonstrate any differences from control, unlike in the 
subcutaneous environment, where their growth was inhibited. Furthermore, hNotch4ICD 
tumors had a slight growth advantage, but were not as oncogenic as mNotch4ICD 
expressing cells. These observations confirm that the tumor growth inhibition activity of 
the Notch2 pathway, and the tumor growth acceleration of the mNotch4ICD pathway was 
not specific to the site of xenograft growth. However, differences were observed for 
tumor site growth in both the hNotchllCD and hNotch4ICD populations. 
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Figure 16. Activation of NotchlCD influences tumor take and tumor growth 
in MDA-MB-231 mammary fat pad tumors. 
MDA-MB-231 cells stably expressing control vector, hNotchllCD, hNotch2ICD, 
mNotch4ICD or hNotch4ICD were grown in the mammary fat pad in athymic 
nu/nu mice. A) The length and width of the tumors was measured at days 19, 26, 
and 33 and volumes calculated. Shown is the quantitation of two independent 
experiments (total n=10/group). Control, hNotchllCD, mNotch4ICD, and 
hNotch2ICD cells showed 100% tumor penetrance. While 100% of the 
hNotch2ICD cells led to tumors at day 19, most regressed with a final tumor 
penetrance of approximately 25%. 
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4.3.2.1 Pathologic features of the mammary fat pad tumors 
Tumors were collected for histological analysis and immunostaining. 
Corresponding to their growth characteristics, the control and hNotch2ICD tumors had 
necrotic central regions that were filled with inflammatory cells and regions of 
hemorrhage (Figure 17). 
4.3.2.2 Microenvironmental feature of the mammary fat pad 
tumors 
PECAM analysis of the vasculature within the tumors revealed that mNotch4ICD 
vessels were large and well developed within the tumors, similar to control. However 
hNotch2ICD tumor vessels were abundant, but small and disorganized (Figure 18A). 
This vasculature was functionally linked to the circulation, as shown by X-ray 
angiography following perfusion into the arterial circulation (Figure 18B). Even though 
the vasculature in both NotchlCD groups was more extensive compared to controls, we 
did note qualitatively that the tumor vasculature in the hNotch2ICD tumors was 
composed of much smaller vessels than mNotch4ICD, consistent with the histological 
analysis. Thus, it is possible that lack of maturity/remodeling of the vessels contribute to 
the necrosis in the hNotch2ICD tumors. 
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Figure 17. Histological analysis of mammary fat pad tumors. 
MDA-MB-231 NotchlCD populations were grown in the mammary fat pad of nu/nu 
mice. Tumors were collected, and processed for hematoxlin and eosin staining. Shown 
are represenatative images from the tumor core (right panels) and tumor periphery (left 
panels). Control tumors were dense and encapsulated. Although both hNotchllCD and 
hNotch4ICD tumors were also encapsulated, these tumors also demonstrated areas of 
necrosis within the tumor. mNotch4ICD tumors were large, and demonstrated invasion 
both into the muscle and the fat pad. 
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Figure 18. Analysis of vascularization in MDA-MB-231 NotchlCD mammary 
fat pad tumors. 
A) MDA-MB-231 tumors stably expressing empty vector control, hNotch2ICD, 
mNotch4ICD, and hNotch4ICD were collected, fixed, and stained using PECAM to 
detect blood vessels. B) For tumor angiography, vasodilation buffer was infused 
into the left ventricle. Immediately following vasodilation, fixation was performed 
followed by flushing with PBS to clear fixation solution. Bismuth contrast agent 
was then injected and the animal was immediately covered in ice to harden the 
contrast agent. X-rays were taken using a specimen radiography system and 
developed using Kodak mammography film. Vessels of control and mNotch4ICD 
tumors are distinctly visible and large, and mNotch4ICD tumor vessels are 
numerous within the tumor. hNotch2ICD and hNotch4ICD vessels are abundant, 
but very small, and hNotch2ICD vessels additionally appear to be leaky as observed 
by angiography. 
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4.4 Structural analysis of NotchlCD 
Recently, Beatus et. al reported the generation of chimeric constructs using the 
intracellular domains of the Notchl and Notch3 receptors (159). They created constructs 
in which they substituted the ankyrin repeats of the two receptors and discovered that the 
origin of the ankyrin repeats determined the ability of the chimeric intracellular domain 
to activate or repress HES activation. The strategy used in this study was similar, and 
chimeric constructs were generated with the intracellular domains of the human Notch2 
and mouse/human Notch4 receptors. The intracellular domains of both receptors was 
separated into three consecutive regions: 1) the sequence beginning immediately after the 
transmembrane domains and right before the beginning of the ankyrin repeat domain (the 
RAM domain and the first NLS), 2) the ankyrin repeat region, including the putative 
seventh repeat, and 3) the C-terminal PEST region, which includes the second NLS, the 
TAD in Notch2 and the PEST sequence. A diagram of the anticipated chimeric constructs 
is show in Figure 19. Three sets of two chimeric receptors will be generated. In the first 
set only the ankyrin repeats have been swapped, in the second only the N-terminal 
regions (which includes the second NLS, TAD of Notch2, PEST sequence and V5 or HA 
tag), and in the third set only the RAM domains of each receptor. A complete description 
of the chimera designations is given in Table 6. The ankyrin repeat swap constructs were 
focused on initially, and verification of the construct was done by 
transcription/translation. 
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Structural motif chimeras: 
RAM domain swap 
Wild type intracellular domains (ICD) 
NotchllCD/Notch2ICD 
—_^ C-terminus 
(RAMI ankyrin | TAD [ S3 ankyrin repeats swap 
Notch4ICD 
RAM = RBPjK-associated molecule 
TAD * transactivation domain 
P = PEST sequence 
C*termimjs swap 
Figure 19. hNotch2ICD and m/hNotch4ICD chimeric receptors. 
The intracellular domain of the human Notch2ICD, mouse Notch4ICD and 
human Notch4ICD receptors were divided into three sections for creating the 
chimeric mutants. The RAM domain begins immediately following the 
transmembrane domain and ends before the first ankyrin repeat (this domain 
includes a nuclear localization signal (NLS)). The ankyrin domain encompasses 
all seven ankyrin repeats. The C-terminal domain contains the rest of the ICD 
following the last ankyring repeat. In the case of hNotch2ICD, this includes the 
transcriptional activation domain (TAD). 
4.4.1 Analysis of reporter activity in 293T cell 
Initial studies evaluating the ankyrin repeat swap chimeric constructs 
(hN2RAMmN4AnkhN2PEST, mN4RAMhN2AnkmN4PEST, hN2RAMhN4AnkhN2PEST) were 
performed in 293T cells as they are highly amenable to transient transfection strategies. 
Distinct differences in Notch effector activation by the hNotch2ICD and mNotch4ICD 
has been observed, therefore initial studies were begun to attempt to determine if these 
differences could be correlated to a specific domain within the ICD. However, it was 
found that CBF1 reporter activity was inhibited by all three chimeric mutants, compared 
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Chimera Name 
m N 4 K A M h N 2 A n k h N 2 H h S l 
hN2KAMmN4AnkhN2FbM 
hN2R A MhN2A n kmN4F b M 
hN2KAMmN4AnkmN41 'bbT 
mN4RAMhN2AnkmN4PbST 
mN4KAMmN4AnkhN2 i 'bS1 
hN2KAMhN4AnkhN21 'bSI 
mN4KAMhN4AnkmN41 'bS1 
Description 
The human Notch2ICD with its 
RAM domain replaced with the 
mouse Notch4 RAM domain. 
The human Notch2ICD with its 
ankyrin domain replace with 
mouse Notch4 ankyrin domain. 
The human Notch2ICD with its 
C-terminal domain replaced with 
the C-terminal domain of the 
mouse Notch4ICD. 
The mouse Notch4ICD with its 
RAM domain replaced with the 
human Notch2ICD RAM 
domain. 
The mouse Notch4 with its 
ankyrin domain replace with 
human Notch2ICD ankyrin 
domain. 
The mouse Notch4ICD with its 
C-terminal domain replaced with 
the C-terminal domain of the 
human Notch2ICD 
The human Notch2ICD with its 
ankyrin domain replace with 
human Notch4ICD ankyrin 
domain. 
The mouse Notch4 with its 
ankyrin domain replace with 
human Notch4ICD ankyrin 
domain. 
Designation (plus clone 
number) 
MHH 
HMH 
HHM 
HMM 
MHM 
MMH 
HHH 
MHM (20-21) 
Table 5. Description of chimeric receptors. 
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both to the 3.5-fold increase observed with hNotch4ICD activation (Figure 20A) and to 
initial results with the hNotch2ICD and mNotch4ICD (Figure 2B). HES1 reporter activity 
was also inhibited by both hN2RAMmN4AnkhN2PEST and mN4RAMhN2AnkmN4PEST. 
Interestingly, the chimera of the human Notch4 ankyrin domain within the human Notch2 
ICD, hN2RAMhN4AnkhN2PEST, demonstrated a 3-fold increase (Figure 20B) in HES1 
reporter activity, similar to the full length Notch2ICD activity. Additionally, activation of 
the HRTl reporter was repressed by all constructs tested except for hNotch4ICD and 
hN2RAMmN4AnkhN2PEST (Figure 20C). In this case, the mNotch4ICD did not activate the 
reporter, as it had in initial experiments in the MDA-MB-231 cells. Differences in the cell 
lines ability to activate the HRTl reporter may exist in this case. Similarly, mNotch4ICD 
and all three chimeras repressed the activity of HRT2 reporter, however a small 
activation was observed for hNotch2ICD and hNotch4ICD (Figure 20D). 
4.4.2 Proliferation analysis of ankyrin domain chimeras in MDA-MB-
231 stable populations 
Reporter analysis suggested that the chimeras may provide insight into the 
differences in tumor phenotype observed with hNotch2ICD and Mnotch4ICD. In vitro 
studies were begun to address proliferation differences by growth curve analysis. Growth 
curve analysis revealed that hN2RAMmN4AnkhN2PEST cells grew more rapidly and, at peak 
growth (450,000 cells/cm2), to a 1.5-fold higher cell density than hNotch2ICD population 
(Figure 21). Conversely, cells expressing mN4RAMhN2AnkmN4PEST had decreased rates of 
growth, with 1.6-fold reduction in cell number (375,000 cells/cm2) at peak cell density 
compared with mNotch4ICD (Figure 21). This suggested that the ankryin repeats may be 
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Figure 20. Chimeric Notch 1 CI) signaling in 293T cells. 
Constructs representing chimeric intracellular domains of hNotch2 and 
m/hNotch4ICD are: HHH (hN2RAMhN4AnkhN2PEST), HMH 
(hN2RAMmN4AnkhN2PEST), and MHM (mN4RAMhN2AnkmN4PEST). These 
constructs and the Renilla reporter were transiently transfected into 293T cells 
with CBF-1 luciferase reporter (A), HES-1 promoter reporter (B), HRT1 
promoter reporter (C), or HRT2 promoter reporter (D), and cell lysates collected 
after 48h for luciferase assay. Luciferase readings were normalized to 
Renilla values, and shown are average data from triplicate samples. Activity of 
the chimeric receptors was compared to the hNotch2ICD, hNotch4ICD, and 
mNotch4ICD constructs. 
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Figure 21. Ankyrin domain of chimera mediates some proliferation effects 
in the MDA-MB-231 cell line. 
MDA-MB-231 cells were stably transfected with hNotch2ICD, mNotch4ICD, 
hN2RAMmN4AnkhN2PEST, and mN4RAMhN2AnkmN4PEST and tested for 
proliferation differences by growth curve. Cells were plated in a 24-well plate at 
30,000 cells/well in quadruplicate. Shown are cells/cm2 at peak growth (day 7 
after plating). The ankryin domain does mediate part of the proliferation effects 
in these cells as a partial restoration of the oncogenic effect of mNotch4ICD or 
inhibition of growth by hNotch2ICD is observed. 
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regulating part of the phenotypic output observed in the NotchlCD stable populations, but 
further studies must be done to completely address this question. 
4.5 Notch regulation of mammary tumor phenotype: does Notch activity 
correspond to tumor aggressiveness and general mammary progression? 
It has been shown in this study thus far that activating the different Notch receptor 
pathways results in distinct tumor outcomes. Specifically, activating the Notch2 pathway 
in the highly aggressive, metastatic line, MDA-MB-231, results in apoptosis in vitro, and 
inhibited growth in vivo. Tumor size, however, could not be correlated to vascularization 
extent of the tumor, as Notch2ICD tumors were just as vascular as the clearly highly 
aggressive mNotch4ICD tumors. This provided a basis for the following two questions 
which have begun to be explored. The first is: does activation of both hNotch2 and 
mNotch4 activated MDA-MB-231 cells metastasize? Secondly, how general is the 
observation observed in the MDA- MB-231 cells? Can this be applied to other human 
mammary tumor lines which display different characteristics such as estrogen receptor 
status, E-cadherin status, etc.? 
To begin to address this question, human breast tumor cell lines were compared to 
the MCF10A line, used as a mammary gland-derived, non-tumorigenic comparison for 
the expression of Notch ligands and receptors. Several well-characterized breast cancer 
lines were analyzed for Notch expression, including MCF-7, MDA-MB-231, ZR75-1, 
MB-468, and BT474. With the exception of the MCF-10A line, all of the human breast 
cancer cell lines demonstrate a tumorigenic phenotype. The BT474 line was derived from 
a primary ductal carcinoma, whereas the MCF-7, MDA-MB-468, and MDA-MB-231 
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were derived from the pleural effusion of metastatic adenocarcinomas, and the ZR-75-1 
line was derived from ascites of a metastatic ductal carcinoma.Notchl protein was 
detected in all lines except BT474, and lower levels of Notch2 were found in all lines 
except MCF-7. Notch4 was also widely expressed, particularly in the BT474 cells, while 
absent in ZR75-1. The Notch ligand Jaggedl was expressed in the MCF-10A, MDA-MB-
231 and MDA-MB-468 lines. Therefore it was concluded that Notch expression can vary 
widely between tumor cell types. 
Next, the OncoMine cancer gene microarray meta-analysis public database was 
utilized to query Notch2 levels in human mammary tumors (Figure 22A). Previous 
studies of human breast cancer patients showed a correlation of strong Notch2 expression 
in well-differentiated tumors and determined that Notch2 was associated with better 
survival outcomes (139). Miller et al. originally determined gene expression patterns in 
Elston Grade 1 tumors (67 cases), Elston Grade 2 tumors (128 tumors) and Elston Grade 
3 tumors (54 cases). The data show that Notch2 mRNA expression decreases as tumor 
grade increases, which is consistent with the previous clinical correlation. 
The human mammary tumor cell lines were utilized to determine if Notch2 
expression had any relationship to cell source or phenotype (Figure 22B). Real time PCR 
showed that the cell line derived from the primary tumor, BT474 demonstrated the 
highest levels of Notch2, while the highly aggressive, metastatic lines showed lower 
expression levels of Notch2. 
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Figure 22. Notch2 expression correlates with tumor aggressiveness in human 
breast cancer. 
A) Notch2 mRNA levels were analyzed using gene expression data sets from cancer 
gene microarray meta-analysis database that was originally described by Miller et al. 
(160). 67 cases of Elston Grade 1, 128 cases of Elston Grade 2, and 54 cases of Elston 
Grade 3 were included in this study. Y-axis represents normalized expression units. 
Shaded boxes represent interquartile range making the 25th-75 percentile; whiskers 
represent the 10th-90th percent range; bars represent the median. The p-value was 
calculated using the Student's t-test. B) Real time PCR for Notch2 in a panel of human 
breast tumor cell lines. 
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Figure 23. Neovascularization in MB231 tumors. 
MDA-MB-231 cells stably expressing mNotchlCD were grown as xenografts in 
the mammary fat pad of nu/nu mice. At tumor collection (Day 33), tumors were 
fixed overnight in 4% paraformaldehyde, and processed for embedding in paraffin 
by serial dehydration in ethanol. Sections were rehydrated and BrdU 
immunohistochemistry perfomed to detect labeled cells. Shown are 20X (panels 
(A) and (B)) and 40X (panels (C) and (D)) magnifications. In panels (C) and (D) 
white arrows point to labelled tumor cells that have escaped the tumor and are 
within vessels. Black arrows point to labelled endothelial cells within the vessel. 
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Figure 24. Schematic of retroviral vector for mammalian expression of 
reporter construct. 
Triple modality reporter construct for whole-body fluorescent (GFP), 
bioluminescent (luciferase) or nuclear (thymidine kinase) imaging (161). 
4.5.1 Models for evaluating metastasis in vivo 
Increased vascularization in the MDA-MB-231 tumors expressing Notch2ICD 
and Notch4ICD has been shown, and this indicates a potentially enhanced ability to 
metastasize. Furthermore, BrdU immunohistochemistry on mNotch4ICD tumor sections, 
reveal BrdU positive endothelial cells in the vessels in the tumor. Plus, BrdU staining 
shows proliferating cells in vessels and active neo-vascularization (Figure 23). The ability 
of the Notch gain of function mammary tumor cells to metastasize will be investigated 
using MDA-MB-231 cells co-expressing a luciferase-Green fluorescent protein fusion 
construct (Figure 24). For this model, Notch gain of function populations will be stably 
transduced with this retroviral gene construct to label cells. After selection for GFP, 
expression of the luciferase gene will be normalized in each cell population to generate a 
standard curve of number of cells/luciferase activity. Tumors will be grown utilizing the 
mammary fat pad model described. After palpable tumors have formed (diameter of 
~2.0mm), growth will be analyzed by calculating the volume of the tumor every three 
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Figure 25. Model for investigating NotchlCD regulation of metastasis. 
A) MDA-MB-231 cells stably transfected with luciferase were grown in 
mammary fat pads #1 and #4. After 3 weeks, mice were injected with luciferin 
and tumors were imaged using the Kodak Imager. Shown is an 8 minute 
exposure. B) After imaging, organs were removed from tumor bearing mouse, 
and a mouse with no tumor. Shown are relative luciferase units, normalized to 
protein level. 
days and the animals carefully monitored for changes in health. Ability to metastasize 
will be evaluated using a time course of tumor growth, in which tumors and organs will 
be collected at early, mid and late phases of growth. Additionally, pictures of the mice 
can be taking using the Maestro Imager, which can detect GFP. At the end point of the 
experiment, GFP will again be detected using the Imager, organs collected and luciferase 
assay performed to detect metastases (Figure 25). 
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4.6 MCF-7 model to characterize NotchlCD regulation 
To test the hypothesis that Notch signaling differentially regulates tumor 
phenotype, the MCF-7 cell line was chosen for further analysis. This tumor line 
demonstrates several differences in phenotype in comparison to the MDA-MB-231 line. 
Unlike the MDA-MB-231 cells, the MCF-7 cell line is estrogen receptor positive, E-
cadherin positive, and keratin 19 positive. It also has wild type p53. Western blot analysis 
showed levels of Notch 1, Notch4 and Jagged 1, but interestingly no Notch2 protein. 
Stable populations of MCF-7 cells expressing hNotchllCD, hNotch2ICD and 
hNotch4ICD were generated. To test tumorgenicity in mice, tumor growth was tested in 
the mammary fat pad (Figure 26). MCF-7 cells are estrogen sensitive, so to control for 
naturally occurring varying levels of estrogen in the female mice, mice were 
ovariectomized and implanted with a 60 day release estrogen pellet. It was observed that 
MCF-7 cells expressing both hNotch2ICD and hNotch4ICD grew rapidly, and at peak 
growth (day 37) the tumors had grown to almost 600mm3 compared to control, which at 
peak growth (day 30) were almost half the size at 350mm3. hNotchllCD tumors grew 
slowly and at peak growth (Day 40) were still smaller than 300mm3. Control tumors 
began to regress or stop growing (in the case of hNotchllCD). Also, knocking down 
Notch 1 in these cells resulted in death, and no stable population could be grown. Notch2 
knockdown cells survived, but showed a dramatic growth disadvantage compared to non-
targeting control. 
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Figure 26. MCF7 NotchlCD tumors have distinct growth properties in the 
mammary fat pad. 
MCF7 NotchlCD populations were grown in the mammary fat pad (6 mice per group). 
Mice were ovariectomized and a 60-day time release estrogen pellet implanted 12 days 
before tumor inoculation. At day 42, three mice per group were re-implanted with an 
estrogen pellet. Shown are average tumor growth over time. MCF7 tumor expressing 
hNotch4ICD, and hNotch2ICD grew quickly and to a much larger volume compared to 
control. Contrastingly, hNotchllCD, while growing slowly initially, grew rapidly after 
reaching 400mm3. All tumor conditions, with the exception of hNotch2ICD tumors, 
regressed in the absence of estrogen. 
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4.7 Notch ligand regulation of mammary tumor progression 
A recent study correlated Notch2 expression with more differentiated tumors and 
better survival outcome in breast cancer patients. This is in contrast to report indicating 
activated Notch 1 to be found in human breast carcinomas (162), and high levels of 
Jaggedl and Notchl associating with poorer overall survival (137). The results presented 
here thus far have identified distinct roles played by the different Notch receptors in two 
different mammary tumor lines, MDA-MB-231 and MCF-7. An increased understanding 
of the part the ligands play in activating endogenous Notch receptors to result in tumor 
phenotype would be beneficial information. 
MDA-MB-231 and MCF-7 cells were therefore generated to express the soluble 
and full-length forms of the Notch ligands, Jaggedl and Delta-1. Stable populations were 
generated by sorting for GFP, and just as was observed in the NotchlCD lines, stable 
expression was not amenable to long term culture (Figure 27). It will be interesting to 
determine if tumor growth characteristics of the ligands can relate to the phenotypic 
results observed thus far. 
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Figure 27. Model to study Notch ligand phenotype in MDA-MB-231 and MCF7. 
MDA-MB-231 (A-E) and MCF7 (F-J) cells were transduced with PINCO-GFP retroviral 
expression constructs for the soluble and full length forms of the Jagged 1 (D, E, I, J) and 
Deltal ligands (B, C, G, H). Cells were transduced with virus conditioned medium in the 
presence of lOug/mL overnight. Shown are transduced cell populations after selecting 
for GFP by cell sorting. 
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5. DISCUSSION 
This study demonstrates that activation of the different Notch receptors in a 
human mammary adenocarcinoma cell line results in contrasting proliferation and 
angiogenic phenotypes in vitro and in vivo. This study substantiates the highly specific 
consequences of Notch receptor activity in mammary tumorigenesis and presents the 
findings that activation of Notch 1, Notch2, and m/hNotch4 receptors in the human 
mammary adenocarcinoma cell line MDA-MB-231 leads to dramatically opposing 
effects. The novel observations that: 1) Notch2 activation inhibits the tumorgenic 
properties of MDA-MB-231 cells, regulating cell proliferation, survival, and apoptosis in 
vitro and in vivo, 2) mNotch4ICD, in addition to its previously ascribed transforming 
activity, can increase the malignancy of human breast adenocarcinoma cells in vivo, 3) 
despite having an overall tumor suppressed phenotype, hNotch2ICD tumors were highly 
successful in recruiting blood and lymphatic vessels, showing that tumor growth and 
vessel recruitment may be separable events, and 4) activation of mNotch4 in the MDA-
MB-231 cells results in increased production and secretion of several angiogenic factors, 
including VEGF-C, P1GF, and IL-ip in the tumor, and the expression of VEGF-D from 
the surrounding tumor environment. Finally, this study also confirms the role of Notch in 
regulating mammary tumor phenotype is context-dependent. The basis of these studies 
enables future questions to be addressed, and this study outlines the preliminary models 
in which they can be answered. 
Thus, this thesis provides an increased understanding of the role of Notch 
signaling in MDA-MB-231 cells, with the development of models that will enable future 
studies to dissect signal pathways involved, as well as the conserved sequence motifs of 
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the NotchlCD that may determine tumor phenotype and be important in therapeutic 
strategies. 
5.1 Notch regulation of tumor proliferation, apoptosis, and survival 
In the MDA-MB-231 tumor cell model, cells expressing Notch2ICD decrease 
proliferation and survival and increase apoptosis contrasting to the tumorigenic 
phenotype of Notch4ICD. NotchllCD cells demonstrated a slight increase in cell 
proliferation. Recent studies investigating Notch signaling in oncogenic cell lines have 
demonstrated a tumor suppressor and activator role for Notch 1 and Notch2, yet the 
precise reason for this contrasting behavior has not yet been defined. For example, 
activation of ligand-independent signaling of Notch 1 plays a causative role in a subset of 
T cell leukemia in humans (163), and has further been shown to be essential in glioma 
cell proliferation and survival (164). However a tumor suppressor function has been 
suggested in transformation of fibroblasts and keratinocytes. Yet Sriuranpong et al. (165) 
have demonstrated that Notch 1 and Notch2 activity in small cell lung cancer cells results 
in significant growth arrest and apoptosis. 
Recently, Wong et al. (166) reported the positive correlation of p21waf and Cyclin 
D3 to tumor invasiveness in the breast. To address the question of cell cycle progression 
in the MDA-MB-231 NICD cells, cell cycle analysis and western blotting for Cyclin D3 
and p21waf was performed. Both Notch2ICD and Notch4ICD upregulated the expression 
of the cell-cycle inducer, Cyclin D3. Taken together with the observed loss of p21waf may 
explain the observed increase in S phase cycling cells observed in the Notch4ICD cells. 
Yet unlike Notch4ICD, Notch2ICD cells also demonstrated levels of the cell cycle 
inhibitor, p21waf. Therefore, although Notch2ICD is inhibited in proliferation, most likely 
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due to the observed high levels of apoptosis discussed below, its expression may be 
indicative of an aggressive tumor phenotype. In the study performed by Sriuranpong et 
al. (165), the inhibition of small cell lung cancer cells was found to be a result of 
upregulation of p27kip concomitant with Gl cell cycle inhibition. While the regulation of 
p27kip, none of the cells or tumors express detectable p27kip, as has been previously 
reported (167). 
Interestingly, the Notch2 activation forced a G2/M arrest when this pathway was 
activated subsequent to Notch4 activation. This is a similar effect of chemotherapeutic 
drugs on breast cancer cells. However, unlike some of these drug mechanisms, Notch 
signaling in these cells is not mediating or being mediated by ERK phosphorylation 
,(168). Although levels of p21waf were not tested in the double transfectants, it is possible 
that p21waf expression has been restored in these cells, and the Notch2ICD ability to 
induce apoptosis with a G2-phase cell cycle arrest outcompetes than Notch4ICD ability 
to promote cell cycle progression. 
All of the NotchlCD populations had higher levels of the angiogenic cytokines in 
the conditioned medium compared to control. However, when conditioned medium from 
the NotchlCD cells was put on parental MDA-MB-231 cells, no differences in growth 
were observed. It was hypothesized that this increase in angiogenic cytokines may play a 
role in tumor development. 
5.2 Tumor growth in vivo: regulation of tumor size and tumor/host 
interactions by Notch 
The ability of a tumor to interact with the surrounding stroma to assist in 
continued growth has been repeatedly demonstrated as an essential component to 
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tumorigenesis. Furthermore, studies demonstrating a role for Notch in vasculogenesis 
have shown it to be essential process during development and physiological angiogenesis 
(169-171). Recently, a correlation between Notch signaling and angiogenesis was 
demonstrated in squamous cell carcinoma, indicating that tumor angiogenesis could be 
modulated by activating Notchl signaling (150). In addition, activation of Notch through 
HGF-induced expression of Jagged 1 results in the enhanced lymphatic vessel recruitment 
in a breast tumor model (172). This study shows that activated Notch signaling plays a 
selective role in tumor angiogenesis/lymphangiogenesis. Tumors expressing Notch 1ICD 
had similar blood vascularization compared to control, however unlike control, 
NothclICD tumors were completely devoid of lymph vessels. These tumors were found 
to have increased levels of VEGF-A and -D. Tumors expressing Notch4ICD were highly 
vascularized, and expressed several distinct angiogenic factors not found to be expressed 
in control tumors, including VEGF-C and P1GF. Although tumors expressing Notch2ICD 
grew slowly, the tumors were also highly vascularized. Decreased expression of human 
NRP-1, Ang-1, and VEGF-D by Notch2ICD tumors was also observed. The expression 
of these cytokines may contribute to endothelial cell recruitment and survival, since 
VEGF-C and VEGF-D serve as survival factors for newly formed lymphatic vessels 
within the tumor (173). In the case of the Notch4ICD tumors, BrdU 
immunohistochemistry supports this idea, as proliferating cells could be visualized in 
vessels within the tumor. The hNotch2ICD tumors expressed VEGF-1 and FGF-1, but in 
general expressed fewer components of the VEGF signaling pathway (no VEGF-C, 
VEGF-D, or NRP-2). Tumors expressing mNotch4ICD were highly vascularized, and 
expressed several distinct angiogenic factors not expressed in control tumors, including 
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VEGF-A, VEGF-C, and VEGF-D. VEGF-D is of particular interest in the mNotch4ICD 
tumors, since it was expressed both in the tumor and host stroma in a selective manner. In 
addition to its activity as an angiogenic and lymphangiogenic factor, VEGF-D has been 
characterized as a survival factor for MDA-MB-231 cell (174). 
Additionally, it was found that vessel number and density did not correlate with 
tumor size. These findings are of interest given studies of human breast cancer samples in 
which intratumoral microvessel density did not associate with other biological markers 
such as p53 status, c-erbB-2 protein, or cell cycle kinetics; however, intratumoral vessel 
density and tumor size were significant but independent predictors of overall survival of 
patients (175). Thus, the effects of Notch signaling on events such as metastasis are of 
interest. Although these studies were performed with VEGF-A, it is possible the 
upregulation of VEGF-C creates an increased survival capability in the Notch4ICD cells, 
which the Notch 1ICD and Notch2ICD cells lack. Conversely, the lack of VEGF-C, 
VEGF-D, and Ang-1 in Notch2ICD tumors could contribute to decreased growth and 
increased apoptosis in these tumors. 
Histological analysis of tumors revealed the Notch2ICD tumors to be more 
fibrotic than the other NICD tumors. Fibroblasts are an important aspect of tumor 
progression. They produce growth factors, chemokines, and extracellular matrix that 
facitlitates angiogenic recruitment of endothelial cells and pericytes (176-178). The 
activated stroma surrounding the Notch2ICD tumors was a surprising observation. 
Although N2ICD tumors were smaller and inhibited in growth, the vascular and stromal 
response of the tumors was indicative of an invasive and aggressive tumor. Studies have 
indicated that HGF promotes the malignant transformation of epithelial cells and also 
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promotes cancer progression (179, 180). Differences in the aniogenic cytokines may 
partly explain this result. Unlike Notch4ICD tumors, high levels of HGF were found in 
the circulating plasma of Notch2ICD tumor bearing mice. 
5.3 Notch effector pathways and structural analysis of the Notch intracellular 
domain 
One of the most complex issues in studying well-conserved, multi-gene signaling 
receptors is the myriad of possibilities for signaling diversity. While it is typical to 
evaluate common target genes such as HES family members and CBF-1 as indicative of 
Notch activity, it is widely accepted that there are multiple levels of regulation as well as 
cross-talk between signaling pathways (134, 150, 181, 182). Since the most well 
established targets of Notch signaling include bHLH transcription factors that activate or 
repress gene transcription, signaling diversity may be generated by the selective induction 
of these targets, including HES family members. In the report by Fan et al. (25) 
demonstrating opposite effects of Notch 1 and Notch2 in promoting medullobastoma 
growth, Notch2 expression was selectively shown to induce HES expression. In this 
study, real-time PCR revealed Notch2ICD inhibited HRT1 expression in the tumor 
groups, and although a strong activator of CBF1 response elements, only weakly 
activated HES1 promoter. In comparison, Notch 1 strongly activated both CBF1 and 
HES1. These data provide initial evidence the different receptors are signaling through 
specific effector targets which may possibly be mediating the tumor phenotype in the 
MDA-MB-231 model. 
Therefore, this study began to explore the possibility protein sequence motifs 
within the ICD results in the differential effects of the Notch receptors. The cytoplasmic 
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region of Notch4 receptor is the most divergent when compared to Notch 1 and Notch2, 
therefore it was hypothesized that the tumor phenotype of Notch 1 and Notch2 activation 
would be most similar. While in vitro, Notch2 and Notch4 activation resulted in 
contrasting outcomes, it was a surprise to find that the success of tumor vascularization 
was shared by both Notch2 and Notch4-activated tumors. To identify sequence-specific 
motifs within the intracellular domains of the NotchlCD, chimera receptors were 
generated. This scenario was chosen over a deletion-mutant analysis, as the structural 
components of NotchlCD would be retained. 
5.4 hNotch2 transcript levels correlate to metastatic tumors 
It was surprising to discover that although Notch2 activation inhibited tumor 
growth and S-phase fraction, it also supported microenvionment changes concomitant 
with the increased levels of VEGF-A and vascularization. Therefore the ONCOMINE 
database was checked for gene expression comparisons between primary and metastatic 
breast tumors. Ramaswamy et al. (183) originally reported global gene expression 
changes in primary (128 tumors) versus metastatic (54 tumors) breast tumors. Notch2 
transcript levels were increased in the metastatic tumor, as compared to the primary 
tumor (Figure 28). 
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Figure 28. Notch2 expression increases in metastatic sites. 
A) Notch2 mRNA levels were analyzed using gene expression data sets from cancer 
gene microarray meta-analysis database that was originally described by Ramaswamy 
et al. (160). 128 primary tumors and 54 metastatic tumors were analyzed. Y-axis 
represents normalized expression units. Shaded boxes represent interquartile range 
making the 25th-75 percentile; whiskers represent the 10th-90th percent range; bars 
represent the median. The p-value was calculated using the Student's t-test. 
5.5 Notch regulation of mammary tumor progression and metastasis: future 
directions 
Modulation of Notch signaling has been shown to effect proliferation, 
differentiation, and apoptosis in many different cell types. Deregulated Notch signaling 
has been implicated in a variety of cancers, contributing to oncogenic or tumor 
suppressor functions. One contributing factor to this controversy is that studies have been 
performed in different cells and tissue types with various Notch receptor activation, 
suggesting that regulation of tumor phenotype by Notch signaling is highly dependent on 
tissue type and cellular context. To overcome these issues in understanding distinct Notch 
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signaling pathways, it is necessary to study multiple receptor pathways in single 
cell/tissue types for comparison. Studies of this sort are limited (184) but support the idea 
that within particular cells, the various Notch receptors have quite distinct effects on 
cellular phenotype. 
The findings that human breast tumor phenotype as a result of activating the 
Notch signaling pathway is highly regulated upon the Notch receptor activated is 
important in the understanding of human breast cancer progression. There has been a 
recent surge of interest in Notch as a therapeutic target for cancer (185-187), although the 
controversial nature of Notch as an oncogene versus a tumor inhibitor in different tissues 
is important to consider (188). In mouse models, it has been shown that Notchl, Notch3, 
and Notch4 lead to transformation of mammary epithelial cells and tumorigenesis (80, 
120, 122), although there have been fewer studies addressing the effects of Notch 
signaling in malignant cells. Understanding the effects of Notch in malignant breast 
cancer cells is relevant to cancer therapeutics, since treatment attempts to stop tumor 
progression and angiogenesis, rather than target initial transformation events that are 
unpredictable clinically. 
Notch2ICD cells demonstrated a decreased survival advantage in vitro both in 
clonal density and anchorage independent growth conditions. In contrast, activation of 
the Notch4 pathway in these cells resulted in increased survival capability. Furthermore, 
Notch2ICD populations had high levels of apoptotic cells. Yet both populations had high 
levels of angiogenic cytokines in the conditioned medium. 
Several laboratories have reported increased Akt activity, phosphorylation, and 
protein expression in tumors of the breast, prostate, ovary, and pancreas (189). The 
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Notch2ICD expressing cells demonstrated an unexpected finding, the levels of p-Akt, an 
activator of anti-apoptotic genes, were increased. This was difficult to understand, as the 
Notch2ICD cells were at an obvious survival disadvantage. Metastasis is a highly 
inefficient process, and the ability of a tumor cell to separate from the primary tumor and 
establish at a distant location is a process still only partly understood. However, for this 
to occur, these cells must activate genes that will put them at a survival advantage when 
localizing to a distant site. In highly differentiated tumor lines, Notch2 expression is 
high. This correlates to the phenotype observed when Notch2 pathway is activated, 
resulting in increased apoptosis and survival disadvantage. Accordingly, when Notch2 is 
inhibited in this line, although cell death does not change, the cells do increase in their 
, ability to proliferate. Moreover, it is also interesting that Notch2 regulation may 
compensate for the effects of Notch4. 
In multicellular mammalian organisms, a balance between cell proliferation and 
cell death is extremely important for the maintenance of normal healthy tissues. This 
hypothesis has been extended to tumors (190). It has been found that "in situ" tumors 
exist in many people, yet the majority of these tumors do not progress to disease because 
of both a balance in cell death and proliferation, and the incapacity to recruit their own 
blood supply. For breast cancer in particular, it has been reported that more than one-
third of women aged 40-50, with no cancer-related disease during life, were found at 
autopsy with in situ tumors in their breast (190). The study presented here, which 
demonstrate that cells with the Notch4 pathway activated have a survival advantage in 
conditions where activated Notch2 cells fail to thrive yet maintains an ability to modulate 
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the tumor microenvironment adds an additional component of complexity to this 
hypothesis. 
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Proliferation - Death 
Figure 29. Hypothesized model for the role of Notch2 in mammary tumor 
progression. 
Based on the work presented in this thesis, a proposed model for the role of Notch2 
in the progression of mammary tumorigenesis and metastasis was hypothesized. 
Well differentiated mammary tumors have been suggested to be present in more 
than 50% of the female population from ages 40-50. These tumors for the most part 
go without clinical diagnosis due to their large death to proliferation ratios and lack 
of interaction with environment. In this study, activation of the Notch2 pathway was 
found to result in increased apoptosis of the poorly differentiated MDA-MB-231 
tumor line. Yet in vivo, these tumors retained the ability to induce a stromal 
response, with subsequent recruitment of blood/lymph vessels. This, in conjunction 
with increased survival targets, suggests the scenario in which activation of Notch2, 
in an well-differentiated tumor keeps the tumor in a high cell death to proliferation 
index. However the recruitment of vessels results in the formation of metastases. 
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